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ABSTRACT
Neuromuscular junction (NMJ) dysfunction has been identified as one of the earliest events in
Amyotrophic Lateral Sclerosis (ALS) pathology. However, which tissue type induces NMJ disruption; be
it the motoneurons (hMN), Schwann cells or skeletal muscle (hSKM) remains unresolved. While
mechanisms by which ALS hMN contribute to NMJ dysfunction are well-described in literature, limited
information exist on how the other tissue types in the tripartite synapse (hSKM and Schwann cells)
induce and/or contribute to ALS NMJ disruption. A fair understanding of the role of each tissue type in
NMJ dysfunction would help shape the trajectory of future ALS research and drug discovery.
It is generally accepted that the observed ALS hSKM weakness and atrophy are a result of hMN axonal
retraction. While recent findings postulate the active pathologic involvement of the hSKM in ALS onset
via NMJ disruption, some scientists have questioned the validity of the transgenic model used in most
studies and the translatability of their results. Contrarily, in vitro modeling of this phenomenon using
patient hSKM samples has proved challenging due to the inability to reliably expand and maintain them
before becoming senescent.
Thus, this study sought to investigate the pathology of hSKM derived from patient ALS (ALS hSKM), its
possible contribution to NMJ dysfunction, and whether hSKM-specific treatment confer any therapeutic
benefit to the NMJ. To avoid the main challenges associated with human-based ALS hSKM studies i.e.,
tissue scarcity and established culturing challenges, patient iPSCs were utilized as the tissue source. This
assured a single source for obtaining both cell types necessary for modeling the ALS NMJ. IPSC-derived
wild type (WT) and ALS hSKM were differentiated using a serum-free, small molecule-directed protocol
which centered on the concurrent modulation of the Wnt and bone morphogenetic protein pathways. To
determine whether the ALS hSKM has intrinsic deficits independent of hMN, comparative assessment of
WT and ALS hSKM were carried out. The myogenicity of resultant WT and ALS progenitors were
confirmed via phase-contrast microscopy, immunocytochemistry, and flow cytometry, after which they
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were terminally differentiated in myotubes. WT and ALS hSKM were compared morphologically and
functionally. The inner mitochondrial membrane potential (ΔΨM) and metabolic plasticity of both WT and
ALS hSKM were also evaluated. After the hSKM-only characterization, both ALS and WT hSKM were
co-cultured with either ALS or WT hMNs. This was to study how the previously outlined hSKM deficits
affect NMJ formation, integrity and function in an effort to delineate the sole contribution to NMJ
disruption. With knowledge of the pathologic contribution to NMJ dysfunction, hSKM-specific Creatine
treatments were performed to investigate its therapeutic benefit to the ALS NMJ.
This project advances the field’s knowledge on the hSKM’s role to ALS NMJ disruption and creates
awareness about considering the hSKM in future research and drug discovery exploits. Additionally, this
project resulted in the development of microphysiological platforms that recapitulate known phenotypic
parameters of ALS while allowing the independent treatment and/or interrogation of each tissue type in
the co-cultures.
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CHAPTER ONE: OVERVIEW OF AMYOTROPHIIC LATERAL
SCLEROSIS
ALS, also known as Lou Gehrig’s, disease is an aggressive and progressive multifactorial disease with a three-year average life expectancy after diagnosis [1]. Currently, 222,801
individuals are afflicted with the disease worldwide. In the United States, over 5000 persons are
diagnosed with ALS yearly. With the global increase of life expectancy, the projected number of
adults to be living with the disease by the year 2040, is about 376,674 [2]. There is presently no
known cure for ALS. Available US Food and Drug Administration (FDA)-approved treatments,
Edaravone and Riluzole, although costly transiently slows disease progression. Thus, anticipated
increase in individuals living with ALS comes with an expected increased financial burden on
governments and families, as patients mostly dependent on caregivers. Development of effective
palliative and curative ALS therapies is therefore of urgent necessity.
There are two forms of ALS. Familial ALS (fALS) accounts for about 10% of all ALS
cases while sporadic ALS (sALS) 90% of known ALS cases. Evidence suggests no apparent
differences between the two types of the disease, aside the fact that fALS has an earlier age onset
(Figure 1) [3]. Mutations in over 20 different genes have been discovered to contribute to ALS
pathology [4]. Other known contributors to the disease progression are, but not limited to,
glutamate excitotoxicity, mutant protein aggregation, mitochondrial damage, ER stress and
related protein degradation dysfunction, neuroinflammation-induced superoxide production and
axonal transport dysfunction. However, events leading to these observed altered molecular
mechanisms and how they are linked are widely unknown. In fact, the heterogeneity in
manifestation, symptoms and survival rates make ALS a clinically challenging disease to
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research. This has led to the proposition of two main hypotheses of ALS onset, dubbed the
dying-forward, and dying-back phenomena.
The dying-forward phenomenon proposes that ALS begins proximally from the
corticomotoneurons and spreads distally, leading to motoneuron axonal retraction. This
phenomenon stemmed from clinical studies that reported glutamate hyperexcitability in
corticomotoneurons of ALS patients (Figure 2) [5, 6]. Additionally, only motoneurons that
synapsed with corticomotoneurons showed signs of degeneration. Interestingly, motoneurons
that share no synapse with corticomotoneurons such as oculomotor were reportedly unaffected[7,
8]. Thus, early research efforts explored mitigating glutamate induced excitotoxicity as a means
of reversing disease progression. In fact, Riluzole, the first FDA-approved drug was designed for
this purpose. However, studies have proven that motoneuron-specific expression of mutant
SOD1 is insufficient to cause ALS-like symptoms. Also, motoneuron rescue has been shown to
not prevent disease progression while attenuating neuroinflammation does not delay disease
progression[9].
Meanwhile, some studies have reported the involvement of other tissue types such as
astrocytes, microglia, Schwann cells and skeletal muscle, suggesting ALS is non-cell
autonomous (Figure 3)[10]. Among the above-mentioned tissues, skeletal muscle has been of
particular interest because of the observed alteration in its metabolism and function prior to
symptom onset. Thus, the skeletal muscle has been proposed to induce and/or promote ALS
pathogenesis via NMJ dysfunction, dubbed the dying-back phenomenon. However, this
proposition remains controversial despite the mounting evidence. To begin, one study reported
altered Cyclin dependent kinase-5 (Cdk5) activity, a kinase implicated in myogenesis and AChR
clustering, prior to symptom onset[11]. Another group of scientists showed that Nogo-A, an
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axonal guidance protein secreted by the hSKM is highly upregulated in both patients and
transgenic models before early symptom onset[12]. Nogo-A upregulation was found to positively
correlate with disease severity and acts as an axon repellent[12]. Additionally, ALS skeletal
muscle dysregulation is reported to precede neuromuscular junction (NMJ) disruption, one of the
earliest events in ALS pathology[13]. Furthermore, skeletal muscle-specific expression of the
SOD1 mutation has been proven to be enough to cause clinical symptoms of ALS, alluding to
the dying-back phenomena and the supposed active role of the skeletal muscle in ALS
progression. Studies on hSKM-specific expression of mutant SOD1 transgenic mice models have
been shown to demonstrate altered muscle morphology and metabolism prior to symptomatic
onset[13-15]. Although, the dying-back mechanism has been reported in other neuropathic
disorders, its occurrence in ALS remains debatable. Understanding the role of diseased skeletal
muscle in ALS will enhance the current knowledge base and will also aid in shaping future
research and drug discovery efforts.
While the cause of ALS onset is still arguable, researchers agree that dismantling of the
NMJ is an early event in pathology. The neuromuscular junction is a highly specialized synapse
between axonal terminals of motoneurons and skeletal muscle (Figure 4). Physiologically,
altered synaptic transmission is reported to be an early indicator of NMJ disruption [16]. Recent
studies suggest that pathological changes in the skeletal muscle and/or the terminal Schwann
cells lead to NMJ dysfunction. This is because, formation and maintenance of the NMJ is
governed by molecular bidirectional communication between the motoneuron and skeletal
muscle. Expression levels of neurotrophic factors, glial cell line-derived neurotrophic factor
(GDNF), insulin-like-growth factor (IGF-1), ciliary neurotrophic factor (CNTF) and vascular
endothelial growth factor (VEGF) plummet with ALS progression [17]. Clinical therapeutic
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studies with these factors have shown marginal survival outcomes [18](30). However, specific
overexpression of GDNF, IGF and VEGF in the skeletal muscle has led to improved
survivability and motor function compared with specific overexpression in motoneurons [19],
[20]. These findings harp on the relevance of the role of the skeletal muscle in NMJ
maintenance, while highlighting the necessity of considering the skeletal muscle during disease
studies and drug discovery.
Despite concerns raised about the validity of ALS transgenic animal model outcomes, the
majority of ALS skeletal muscle studies have relied on them. This is partly due to challenges
associated with culturing patient muscle biopsy samples. However, the availability of patient
derived induced pluripotent stem cells (iPSCs) created a great avenue for studying human ALS
hSKM. By ectopically expressing inducible MyOD, Lenzi et al generated and studied mutant
FUSed in Sarcoma (FUS) and Tar Binding Protein-43 (TDP-43) myotubes [21]. They
demonstrated differences in response to acetylcholine stimulation between healthy and FUS and
TDP-43 mutant myotubes [21]. Another study by Pichiarelli et al demonstrated deficits in
endplate maturation specifically, ACh receptor (AChR) clustering in FUS 1 and FUS 2 in
myotubes generated from patient iPSCs [22]. Interestingly, endplate maturation showed no
improvement even in the presence of healthy motoneurons [22]. However, the functional defects
of human ALS muscle independent of the motoneuron and its direct implication on the NMJ
integrity and function is yet to be demonstrated. This study explores the intrinsic deficits of the
ALS hSKM, its contribution to ALS NMJ dysfunction, and the possibility of it being a
pharmacological target in ALS drug discovery.
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Figure 1 Types of ALS and distribution of some associated genetic mutations. Cited from (Renton, A. E., Chiò, A., & Traynor, B. J. (2014). State of play in
amyotrophic lateral sclerosis genetics. Nature neuroscience, 17(1), 17-23).

5

Figure 2 Illustration of the main paradigms of ALS pathogenesis. Cited from (Vucic, S., Ziemann, U., Eisen, A.,
Hallett, M., & Kiernan, M. C. (2013). Transcranial magnetic stimulation and amyotrophic lateral sclerosis:
pathophysiological insights. Journal of Neurology, Neurosurgery & Psychiatry, 84(10), 1161-1170).
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Figure 3. Cartoon demonstrating some ALS associated tissues and pathophysiology. Cited from (Vucic, S., Rothstein, J. D., & Kiernan, M. C. (2014).
Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends in neurosciences, 37(8), 433-442).
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Figure 4 Cartoon illustration of the neuromuscular junction (NMJ). Adapted from (Valdez, G. (2020).
Formation and maturation of neuromuscular junctions. In Patterning and Cell Type Specification in the Developing
CNS and PNS (pp. 157-184). Academic Press).
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CHAPTER TWO: CHARACTERIZATION OF ALS SKELETAL MUSCLE
DERIVED FROM PATIENT INDUCED PLURIPOTENT STEM CELLS
Introduction
ALS is an aggressive, multi-factorial disease characterized by progressive motoneuron
degeneration, muscle weakness and wasting[23]. It typically manifests between ages 40 and 70
and results in death within 2-5 years of diagnosis. Ten percent of all reported ALS cases are
familial (fALS) while the remaining are sporadic (sALS). Currently, genetic mutations in over
twenty genes including superoxide dismutase 1 (SOD1), chromosome 9 open reading frame 72
(C9orf72), fused in sarcoma (FUS), and TAR DNA binding protein 43 (TDP43) are associated
with ALS[3]. However, the pathogenesis of ALS remains largely unknown. It is understood that
disruption of the neuromuscular junction (NMJ) is an early event in ALS pathology[24-27],
however, the mechanisms that lead to NMJ dysfunction are still unresolved. Specifically, there is
disagreement in the literature regarding whether motoneuron (MN) dysfunction causes
neuromuscular denervation, or skeletal muscle dysfunction drives synaptic degradation, thereby
causes retrograde MN dysfunction and death[24, 28, 29]. The specific susceptibility of MNs in
ALS led early researchers to adopt a “neurocentric” approach to investigating the disease [30,
31]. However, mounting evidence suggests the involvement of the skeletal muscle in ALS onset
via NMJ disruption[1, 32, 33]. Fischer and colleagues published evidence of disrupted NMJ
without signs of MN death in a spatiotemporal study performed in ALS murine models[1, 26,
27]. In the same report, they presented pathology results from an ALS patient that demonstrated
skeletal muscle atrophy without MN cell death[26]. In another, the muscle-specific
overexpression of mutant human SOD1 protein was stated to be sufficient to drive disease
symptoms in a transgenic mouse model [15, 34]. Since then, many investigators have reported
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observations of skeletal muscle metabolic dysregulation and atrophy before MN degeneration in
ALS animal models[35, 36]. In a study by Deloach et al, they reported that ALS skeletal muscle
secreted axonal chemorepellents molecules such as Nogo-A, that stunt axonal growth[37]. Also,
there are reports of altered morphology and regenerative capabilities of satellite cells derived
from patient skeletal muscle biopsies[38, 39]. Despite the above-mentioned findings, the role of
skeletal muscle dysfunction in ALS remains elusive due to the scarcity of human-based studies
that substantiate the phenomenon, the presence of other cell types that complicate the
investigation of muscle pathology, and the lack of models that can reproduce the evolvement of
muscle pathology from the beginning of muscle development.
This study aimed to investigate the regenerative and functional deficits of the ALS
skeletal muscle by developing a functional in vitro phenotypic skeletal muscle model from ALS
patient-derived iPSCs (ALS-iPSCs) harboring mutations in the SOD1 gene. This patient iPSCderived muscle model is human-based, free of other cell types such as motoneurons, and allows
the investigation of muscle pathology from myogenesis to functional muscle formation. With the
iPSC-derived model, we demonstrate that ALS-iPSC myoblasts have deficits in fusion despite
their expression of appropriate myogenic markers. Additionally, significant morphological and
structural alterations were identified in iPSC-derived ALS-myotubes that correlated with
decreased contractile and metabolic function. Furthermore, subcellular investigation revealed
ALS skeletal muscle had altered mitochondrial function, which may negatively impact metabolic
pathways and energy generation. Compared to previous iPSC-derived muscle studies, this
investigation provides a detailed and comprehensive view of the morphological and structural
deformity of ALS-muscle, and demonstrates for the first time their functional defects in
contractibility, as well as their metabolic dysregulation. The abnormalities revealed in these
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patient iPSC-derived muscle models indicates that endogenous expression of the mutant SOD1
gene in muscle, independent of the influence of motoneurons, has a toxic effect on skeletal
muscle regeneration and function, which supports the active role of muscle in NMJ degradation
and ALS onset and/or progression.

Result
Characterization of WT and SOD1-mutant iPSC myoblast lineage determination
Three iPSC lines, wild type control A (WT Ctrl A), superoxide dismutase (SOD1) mutation
with glutamate 100 to glycine switch (E100G) and SOD1 with lysine 144 to proline switch
(L144P) were differentiated into myogenic progenitors (myoblasts) by the simultaneous
activation of WNT signaling and inhibition of bone morphogenetic protein (BMP) pathways
using a serum-free, small molecule-directed protocol adopted from Chal et al (Figure 5A)[40].
Correct iPSC to myogenic lineage progression was confirmed and quantified by evaluating the
timely expression of known differentiation markers including T-box transcription factor 6
(TBX6), myoblast determination protein 1 (MyoD) (proliferative satellite cell marker) and paired
box protein 7 (Pax7) (satellite cell marker) via flow cytometry (Figure 5D). WT, SOD1 E100G
and L144P cultures were found to have comparable percentages of cells expressing each
myogenic marker (Figure 5E, F). At the end of the myogenic progenitor differentiation,
myoblasts from all three lines were seeded at low density for morphological assessment via
phase-contrast and fluorescent microscopy. While WT myoblasts were generally spindle-shaped,
the SOD1 myoblasts were a mix of spindle-shaped and flat-like, irregularly shaped cells (Figure
5B). Regardless of morphology, immunocytochemistry results indicated that WT and SOD1
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myoblast cultures were MyoD and Pax7 positive confirming the flow cytometry data (Figure
5C). Together, these data indicated that myoblasts derived from healthy and ALS-mutant PDiPSCs were proliferative and expressed markers essential for correct myogenic progression
differentiation.

Characterization of WT and SOD1-mutant myogenic progenitor fusion
The ability of satellite cells to initiate proliferation and progress through the myogenic
differentiation program is essential to skeletal muscle repair and mass maintenance after
injury[41]. Thus, SOD1 myoblasts were tested for their ability to differentiate into myotubes.
While WT cultures had nascent myotube formation on day three after switching to differentiation
medium, none were observed in SOD1 cultures until the fifth day in differentiation medium
(Figure 6A). Cultures were maintained for 14 days to accommodate the slower differentiation of
the SOD1-mutant cultures. On the14th day of differentiation, the fusion indices of all cultures
were quantified (Figure 6B). Compared to WT, SOD1-mutant myoblasts had a significantly
lower fusion index (p<0.001) (Figure 6F). Additionally, the number of myotubes per area in each
culture was quantified as another measure of fusion efficiency. While WT cultures were dense
with myotubes, SOD1-mutant cultures had 3X less myotubes (Figure 6G). To ensure that the
decreased fusion in the mutant cultures was not due to the presence of non-myogenic cells, the
culture was stained with the myogenic-specific marker, desmin. Both myotubes and unfused
myoblasts in the cultures stained positive for desmin (Figure 7). The results confirmed that the
observed reduced fusion in ALS cultures was not due to the presence of contaminating cells, but
the inability of the myoblasts to progress through the differentiation program. Altogether, ALSmutant cultures exhibited altered/decreased fusogenicity compared to WT cultures.
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Morphometric Assessment of WT and SOD1-mutant myotubes
The phenotypic characteristics and structural organization of SOD1 myotubes were evaluated
to delineate morphometric alterations when compared to WT. Measurements of the average
width, thickness and length of myotubes from each cell line were assessed. While SOD1
myotubes were slightly narrower than WT myotubes, they were significantly thinner and shorter
(p=0.018, <0.001 respectively) (Figure 6 C, D, E). The complex spatial organization of
myogenic-proteins is vital to their ability to accurately execute function [42]. Thus, the structural
organization of Myosin Heavy Chain (MyHC) within myotubes from each culture, as well as
nicotinic acetylcholine receptor (nAChR) clustering, were analyzed via immunocytochemistry.
MyHC appeared densely arranged and compact in the WT myotubes. Additionally, WT
myotubes expressed nAChR clusters throughout the culture (Figure 8). Conversely, SOD1
myotubes had disorderly and loosely arranged MyHC that made striations within individual
fibers appear discontinuous. Also, there were few to no nAChR clusters on SOD1 myotubes, and
nAChR staining appeared diffuse and faint (Figure 8). Collectively, these results demonstrate
that SOD1-mutant myotubes have altered morphological and structural deficits that may affect
function.

Functional Evaluation of WT and SOD1-mutant myotubes

Muscle weakness is an established ALS hallmark and has been described in both patients and
transgenic animal models. From the neurocentric viewpoint, muscle wasting, and weakness are a
result of motoneuron denervation. However, this opinion has been challenged by recent findings
that postulate there are pathological alterations in diseased skeletal muscle function devoid of
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axonal retraction. To test the latter hypothesis, individual myotubes from all lines were subjected
to stimulated contraction at frequencies of 0.3, 0.5, 1,2 and 4 Hz on day 14 of differentiation
(Figure 9A) and the functional activity of WT myotubes was compared to that of SOD1
myotubes. WT myotubes contracted consistently with increasing frequency, however SOD1
myotube twitches were asynchronous and had comparatively weaker amplitudes (Figure 9A, B).
As expected, contractile force output for SOD1 myotubes was also comparatively low (Figure
11A, B). Because the SOD1 myotubes were noted to mature at a slower pace, myotubes were
tested at day 21 of differentiation(Figure 10A, B). This was done to determine if a longer
maturation period could improve contractile synchrony and amplitude in the SOD1 cultures.
While contractile synchrony appeared to improve in SOD1 L144P myotube cultures, the
amplitude remained the same (Figure 10A. Conversely, SOD1 E100G cultures showed no
improvement in either contraction synchrony or amplitude with increased time in culture (Figure
10A, B). These results suggest that SOD1 myotubes have intrinsic defects that retard maturation
and contractile function independent of denervation.
Mitochondrial Function Analysis of WT and SOD1-mutant myotubes

Studies have reported changes in mitochondrial morphology, dynamics and function in ALS
pathology[25, 43-45]. Additionally, the processes of muscle fusion and contraction are energyintensive activities[46, 47]. Thus, the mitochondrial function of SOD1 cultures was investigated
as a possible subcellular mechanism for the phenotypic observations in muscle regenerative and
contractile function. The mitochondrial membrane potential (ΔΨm) of diseased and WT
myotubes was assessed because the ΔΨm has been shown to be vital to a myriad of cellular
processes including energy production, calcium handling and DNA repair[48, 49]. Results
14

indicated significantly lower average ΔΨm values for both SOD1 myotube lines compared to
WT (Figure 12A). Mitochondrial function of the SOD1 myotubes was evaluated by measuring
the rate of metabolism of various substrates. Overall, tricarboxylic acid (TCA) cycle
intermediates and fatty acids were metabolized at either a slightly faster or the same rate by
SOD1 mitochondria compared to WT (Figure 12B, C). However, SOD1 cultures metabolized
amino acids, ketones and glycogenic substrates at a slower rate compared to WT (Figure 12 D,
E, F). Among the assayed substrates, lactate metabolism was particularly low in diseased
cultures compared to WT (Figure 12B). Together, these results suggest that mitochondrial
dysfunction is a characteristic of SOD1 mutant skeletal muscle.

Discussion
The goal of this study was to create a phenotypic model of ALS muscle to investigate the
inherent defects of the ALS skeletal muscle in regeneration and function to better evaluate their
contribution to NMJ disruption in ALS. To achieve this, functional in vitro biomimetic ALS
skeletal muscle models were developed from fALS patient-derived iPSCs. Two patient iPSCs
lines harboring mutations in the SOD1 gene resulting in amino acid substitutions at L144P and
E100G, were differentiated into skeletal muscle myoblasts and subsequently myotubes.
Systematic analysis of the ALS-myoblasts revealed deficits in myogenesis, myotube
morphology, structure and function, as well as mitochondria properties and metabolism.
Myotubes had notably decreased acetylcholine receptor (AChR) clusters and loosely arranged
myosin heavy chain proteins compared to WT myotubes. BioMEMs multiplexed cantilever
analysis indicated ALS-iPSC myotubes have significantly weaker force output and reduced
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contraction synchrony compared to WT controls. These defects identified in iPSC-derived ALSmuscle, in the absence of other cell types, indicate muscle is an active contributor to the initiation
and/or progression of NMJ dysfunction in ALS.
ALS-iPSC myoblasts were found to be proliferative and expressed the appropriate stagespecific myogenic markers at percentages comparable to WT. However, the flat and stretched
morphology observed in the ALS-myoblast cultures reiterates the senescent-like morphology
reported in a patient myoblast study by Pradat et al[38]. We also demonstrated that ALS-iPSC
myoblasts exhibited delayed and decreased fusibility when subjected to differentiation. It has
been established that correct myoblast activation and fusion are pertinent to skeletal muscle mass
maintenance and repair [50]. Thus, any impairment in the myogenic developmental program may
have adverse effects on downstream regeneration. Most SOD1 myoblasts were unable to fuse
upon induction, suggesting there may be defects in skeletal muscle regeneration in ALS
pathology. The diminished fusibility of SOD1 myoblasts observed in the current model could
affect muscle mass maintenance and repair in patients, which may partly explain observed
muscle atrophy. This has been reported in previous patient skeletal muscle biopsy studies[38,
39].
Morphometry results showed that the mutant myotubes had narrower widths and shorter lengths
compared to WT controls. At a higher magnification, MyHC proteins appeared loosely arranged
in SOD1 myotubes than in WT. Contrastingly, Pradat et al, reported that ALS myotubes were
long and thin, while the SOD1 myotubes in our cultures were shorter and narrower than WT[38,
39]. Notwithstanding, immunocytochemistry results from both labs demonstrated lower
expression level of MyHC in ALS myotubes. This could explain the loose arrangement of
MyHC and reduced thickness of myotubes observed in our culture system[38, 39].
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Another notable observation was the reduced expression of AChR on SOD1 myotubes
compared to WT myotubes. AChR clusters expressed on ALS-iPSC myotubes were smaller and
appeared diffuse compared to the WT (Figure 8). Robust expression and dense clustering of
AChRs are necessary to receive action potential signals from the presynaptic motoneuron.
Reduced expression and clustering decreases the possibility for accurate transmission of
motoneuron signaling events. Abnormal AChR function has been described in both patient
samples and mice models[16, 51]. Recently, Picchiarelli et al reported decreased AChR
clustering and endplate maturation in FUS-mutant skeletal muscle generated from patient iPSCs
as possible cause of NMJ dysfunction[52].
In addition, integration of ALS muscle with BioMEMs cantilevers revealed cell-autonomous
deficits in contractile force output and time-to-peak force. Although slowed contraction has been
reported in the SOD1 G93A transgenic murine model, this is the first work to directly
demonstrate defective contractile function of ALS muscle in a human-based system[53]. While
skeletal muscle weakness is an established hallmark of ALS, the exact cause of this dysfunction
is unclear. The generally accepted hypothesis is that muscle weakness in ALS is a result of MN
denervation and axonal retraction[54]. However, contrary to this view, muscle-centric studies
suggest an intrinsic cause of muscle weakness[15, 34, 55]. In the current model, ALS-iPSC
myotubes exhibited over 70% lower contractile force compared to WT. Evaluation of the timeto-peak force (TTP) showed a significantly delayed TTP in SOD1 myotubes (Figure 11C). This
observation is suggestive of irregularities in the excitation-contraction-coupling (ECC)
machinery and/or calcium regulation. It is noteworthy that while pathological ALS MNs could
be an inevitable component of muscle weakness in vivo, this study provides solid evidence
confirming significant innate muscle deficits independent of motoneurons. By reproducing
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human myogenesis from the stem cell stage, this systematic study revealed that ALS-myotubes
have deficits in myotube regeneration, the capability of receiving innervation, contractibility
upon excitation, and in the force of contraction. It is conceivable that the combination of these
muscle-derived deficits and those from neuron-derived components result in the muscle
weakness symptoms seen in ALS patients.
Furthermore, we identified mitochondrial dysregulation in these ALS-muscle. First, TMRE
staining indicated a significantly decreased ΔΨm in SOD1 cultures compared to WT myotubes.
ΔΨm is known to play a pivotal role in oxidative phosphorylation, therefore, a reduced ΔΨm
would imply the inability of ALS skeletal muscle to provide energy support for its function[48].
More importantly, decreased ΔΨm interferes with Ca2+ handling, which is an important regulator
of aerobic respiration[48, 49]. Decreased ΔΨm has also been observed in the muscle of SOD1
mice models in the absence of axonal retraction, suggesting skeletal muscle dysfunction could
precede NMJ disruption[44]. Additionally, altered mitochondrial morphology, dynamics and
function have been reported in ALS patient muscle studies and murine models[44, 45, 56].
We also demonstrated that ALS iPSC-myotubes have reduced metabolic plasticity. With the
provision of citric acid cycle intermediates or fatty acids, the rate of metabolism in SOD1
cultures was either the same or had a slightly faster rate compared to WT. However, metabolism
of glycogen, lactate, amino acids, and ketones were relatively slower in SOD1 cultures. The
inability of ALS-iPSC muscle to metabolize lactate stood out among all glucogenic substrates.
Once thought to be a by-product, lactate has more recently been found to be major energy source
for skeletal muscle. Reduced lactate turnover has been reported in fALS patients and lactate
metabolism was observed to significantly decrease with disease progression[57]. Consistent
reports concerning mitochondria defects in muscle phenotypes from different ALS models
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suggest a mechanistic link between these two pathologies. While the mechanism of the observed
changes in ALS mitochondrial function is unclear, the results imply that provisions for selective
nutrient substrate utilization could partially circumvent the muscle metabolism obstacle and
possibly alleviate this pathology. This idea is supported by the effectiveness of a holistic therapy,
the Deanna Protocol, which contains the citric acid cycle intermediates as a supplement[58].
While there is documented evidence of skeletal muscle dysfunction in ALS patients, how the
underlying ALS-associated genetic mutations induce dysfunction is poorly understood. This
makes outlining the pathogenic role of muscle challenging, despite the accumulating evidence
suggesting its active participation in ALS pathogenesis[23, 26, 55]. Although, some researchers
have reported altered morphology, myogenicity and regeneration of ALS patient myoblasts in
vitro, the genetic background of the subjects was not discussed[38, 39]. Also, no study has
reported direct contractile assessment of human-derived ALS myotubes in vitro, although one
researcher has extrapolated functional defects by measuring the passive electrical properties of
ALS skeletal muscle generated from patient iPSCs[21]. This current ALS iPSC- skeletal muscle
model demonstrates deficits of the ALS skeletal muscle by directly measuring its regenerative,
contractile and metabolic function.
Overall, we have developed a patient iPSC-derived skeletal system that recapitulates typical
ALS pathology in two phenotypes and also for subcellular mechanisms. Because this is a
phenotypic model allowing for the quantification of muscle function, it could be utilized in high
content drug toxicological and efficacy screening. In addition, when coupled with HoaC and
BioMEMs technologies, it may be used in engineering physiologically relevant multi-organ
models for studying complex interactions among tissues during ALS onset and progression.
Compared to patient biopsy samples, sourcing from iPSCs eliminates the limitation for the cell
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source availability and enables the possibility of generating multiple cell types from the same
iPSC, patient-specific models. Collectively, this system provides a valuable platform for ALS
translational study and therapeutic development.

Conclusion
In conclusion, this work demonstrates that ALS patient-derived skeletal muscle has inherent
defective regenerative capabilities and function independent of motoneuron influence or
denervation. This patient iPSC- derived SOD1 skeletal muscle model recapitulates most ALSdiseased muscle characteristics reported in human clinical and transgenic animal studies. Thus,
this iPSC-derived muscle system is a good resource for etiological investigations and relevant
high content drug testing.

Materials and Methods
Cantilever Fabrication and Surface Chemistry Engineering.
Cantilever microelectromechanical systems (MEMS) were made from 6-inch silicon-oninsulator wafers, polished with a 5μm silicon layer and a 500μm silicon dioxide layer on the
front and back respectively, as previously described[59]. The cantilever patterning was done
using S1818 photoresist, followed by deep reactive ion etching. Glass coverslips were soaked in
12M hydrochloric acid and placed on a shaker overnight. The next day, the coverslips were
thoroughly rinsed with sterile water, and transferred to 100% ethanol. After 24 hours, the
coverslips were allowed to dry overnight and stored in a desiccator.
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IPSC-derived Myoblast Differentiation
Human induced pluripotent stem cell (iPSCs) lines ND41865, ND35662, ND39032 were
obtained from the Coriell Institute for Medical Research. iPSCs were passaged a maximum of 12
times per recommended NIH passaging protocols. Cells from passages 6 to 12 were used in
myoblast differentiation experiments. Myoblast differentiation was performed strictly following
a protocol published by Chal et al[40]. Briefly, iPSC cultures were maintained in mTESR1 (Cat#
85850, StemCell Technologies) or TESR-E8 (Cat# 05990, StemCell Technologies) on matrigelcoated (Cat# 354230 Corning Life Sciences) surfaces to a 15-20% confluence before
commencing myoblast differentiation. Cultures were maintained until 35-40 days of
differentiation and harvested. At the end of myoblast differentiation, the cultures were re-plated
at 1:6 in MyoCult serum free-supplemented 1000mg/L DMEM (Cat #05982; 05982 StemCell,
Technologies) for myoblast expansion. Medium was refreshed every other day until 50-60%
confluence. Myogenic progenitors were harvested and cryopreserved for downstream
applications. All cultures were maintained in humidified air supplemented with 5% CO2, at 37
°C.

IPSC-derived Myotube Maturation.
Myoblasts were plated on acid-washed coverslips in Myocult medium (1000mg/L
DMEM supplemented with MyoCult Serum Free nutrient cocktail) until confluent. Next,
cultures were switched to DK-HI medium (DMEM/F12 21041-025 ThermoFisher
Scientific,15%vol/vol Knockout Serum Replacement ThermoFisher Scientific 10828-028,
10ng/ml hepatocyte growth factor (HGF) Peprotech 315-23, 2ng/ml insulin-like growth factor
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(IGF), Sigma I1271, 0.1mM β-mercaptoethanol, ThermoFisher Scientific 31350010, 1% MEM
Non-Essential Amino Acids Solution ThermoFisher Scientific 11140050 and 100nM
dexamethasone, Sigma D4902). After two days, cultures were switched to the terminal
differentiation medium, N2 (DMEM/F12 21041-025 ThermoFisher Scientific, 1% Insulin
Transferrin Selenium (ITS) 41400045 ThermoFisher Scientific, 1% N2 supplement 17502048,
ThermoFisher Scientific, 1% L-glutamine 20mM A2916801 ThermoFisher Scientific,100nM
dexamethasone, Sigma D4902).

Myoblast Myogenic Characterization.
Cultures, during the course of myoblast differentiation, were subjected to flow cytometry
(FC) to confirm temporal activation of the myogenesis gene program. Differentiation markers
assessed were the pre-somite marker, TBX-6 (Abcam ab170482), after 4-8 days of
differentiation and the myogenic progenitor markers, Pax7 (Invitrogen PA5-117P) and MyoD
(Santa Cruzsc77460; LS Bio LS C263888), after 18-21 days in differentiation. Differentiating
cultures were lifted using TrypLE Express or Trypsin-EDTA 0.05% (ThermoFischer
Scientific12605010, 25300062) and centrifuged at 280g for 5 minutes. The resulting pellet was
re-suspended in FC buffer (10% BSA). An equal volume of 4% paraformaldehyde, (PFA) in 1X
phosphate buffered saline (PBS) solution was added to the suspended culture and incubated at
4°C for 15 minutes. Cultures were pelleted and rinse twice with FACs buffer, followed by a 4°C
15-minute incubation with 0.2% saponin solution to permeabilize the cells. Cultures were
centrifuged, rinsed twice and re-suspended in FC buffer following the permeabilization step. Fc
receptor blocker (Miltenyi Biotec, 130-059-901), was added at a 1:5 dilution factor and
incubated at 4°C for 20 minutes. Antibodies were added at 0.1 to 10μg/ml, incubated for 60
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minutes at 4°C, rinsed 2x and re-suspended in FC buffer. The resultant cell solution was added to
a 96-well plate and analyzed using a flow cytometer (Beckman Coulter CytoFlex). The data was
analyzed using the CytoFLEX instrument software.

Immunocytochemistry and Confocal Microscopy
Mutant and WT cultures on glass coverslips were fixed with 4% PFA solution for 15
minutes and rinsed 3x with 1x PBS solution. Cells were then blocked with donkey serum
blocking buffer (2.5mL Donkey Serum+ 2.5 mL BSA+ 40 mL sterile water +5mLs PBS 10x) for
1 hour after a 15-minute permeabilization period with 0.1% triton in PBS. Primary antibodies for
MyoD, Pax7, desmin (Thermofisher Scientific PA5-16705, MyHC DSHB, A4.1025-s), and
Ryanodine receptor (RyR)(Millipore,AB9078), dihydropyridine receptor (DHPR) (Thermofisher
Scientific,MA3920) were added to blocked cultures and incubated overnight at 4°C. The
secondary antibodies donkey anti-mouse and anti-rabbit (Thermofisher Scientific, A10037, A21206) were added the next day at a 1:250 dilution. Coverslips were rinsed 3x in 1x PBS
mounted on glass slides with Prolong gold mounting medium with DAPI (Life Technologies
P36931) after a 2-hour incubation period for imaging. Images were taken with Axioskop 2 mot
plus upright spinning disk confocal microscope (Carl Zeiss) that had been connected to a XCite
120 Fluorescence Illumination system (EXFO) beam with multi-spectral laser scanning software
(Perkin Elmer)
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Myotube Phenotypic Characterization
Five representative phase-contrast images per coverslip were taken from all myotube
cultures with a Zeiss Axioscope 200. Images were loaded using ImageJ and analyzed for
myotube length, width and average myotube number using the cell counter and NeuronJ plugins.
Fusion index was quantified by staining myotubes with MyHC antibody (DSHB, A4 1025-S)
and nuclear stain, 4′,6-diamidino-2-phenylindole, (DAPI). The number of nuclei within
myotubes was divided by the amount of total nuclei to obtain a number between 0 and 1, where 0
means no fusion and 1 is fusion of all myoblasts.

Myotube Contraction Assessment.
After 14 days in differentiation medium, mutant and WT myotubes cultures in petri
dishes were placed on a 37 °C heated stage (ThorLabs TC200) on an upright phase-contrast
microscope (Zeiss Hal 100). Myotube contraction was elicited using silver electrode-driven, 1V
broad field stimulation at frequencies of 0.3, 0.5, 1.0, 2.0 and 4.0 Hz for 15 seconds. Myotube
contractions were captured using a high-speed acquisition digital camera (Hamamatsu model
C8484-05G) from a selected region of interest (ROI). This procedure is described in detail by
Santhanam et al [60]. Contraction synchrony was calculated by dividing the number of
contractions by the total number of expected contractions at a given frequency.
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Myotube Force and Fatigability Assessment
Mutant and WT iPSC-derived myoblasts were seeded at 400 cells/mm2 on collagen Icoated BioMEMs cantilever devices and assembled into engineered acrylic housings. The
cultures were maintained in proliferation medium for 5 days, switched to DK-HI medium for 2
days, and then into terminal differentiation medium, N2, for 14 days. At the end of the
differentiation period, the skeletal muscle myotube cultures were tested for contraction. As
previously described, the cultures were transferred to a heated stage, equipped with a light source
(above), and photodetector and laser (below). System control and data collection were performed
as described by Wilson et al [61]. Skeletal muscle from both mutant and WT cultures tested for
their maximum contractile force output (MCF) with a frequency of 0.5Hz and pulse width of
250ms, at 5V.

Mitochondrial Membrane Potential Assessment.
Mutant and WT iPSC-derived myoblasts were plated at 50 cells/mm2 on Collagen Icoated 18mm glass coverslips and differentiated into myotubes. At day 12 of differentiation,
myotubes were incubated in 500nM tetramethylrhodamine (TMRE) (Thermofisher Scientific,
Cat# T669) solution for 30 minutes and rinsed twice with 1X PBS. Fluorescence images of the
myotube cultures were taken with a Zeiss spinning disk confocal microscope (Axioskop 2 Mot
Plus). Average fluorescence intensity per image was measured via imageJ.
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Mitochondrial Metabolic Profiling.
Mitochondrial metabolism of mutant and WT iPSC-derived myotubes was assessed by
measuring the rate of electron flux through the electron transport chain (ETC) following
treatment with specific substrates. Assay solutions and preparation were done per manufacturer’s
instructions (BiOLOG, Cat#s 14105, 72303, 74353). Briefly, muscle cultures were harvested
using TrypLE Express and centrifuged at 280g for 5 minutes. The resulting pellet was resuspended in 1x BiOLOG mitochondrial assay solution (MAS). The cell suspension was added
to a 96-well plate with the various substrates, incubated in BiOLOG assay mix containing
saponin, sterile water, MAS and BiOLOG’s redox dye MC. Data was collected over a two hour
period, with optical density measurements taken every 5 minutes by the HT Synergy plate reader
at 590 nm. Initial rate of each reaction of substrate was calculated from the resultant curves at the
end of the experiment.

Statistical Analysis.
Morphometry results were analyzed by One-Way ANOVA followed by Dunnett’s test.
Functional data from the pixel subtraction apparatus was evaluated with ANOVA on ranks
followed by the Holm-Sidak method. Cantilever experimental results were analyzed with OneWay ANOVA followed by Dunnett’s test.
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Figure 5 Myoblast Derivation and Myogenic characterization. (A) Illustration of the differentiation protocol used
in both myoblast and myotube phases of differentiation. (B) (left panel) Phase contrast images of iPSC cultures of
the various cell lines in maintenance medium. (B) (right panel) Phase contrast microscopy images of resultant
myoblast cultures after replating in proliferation medium at the end of the myoblast differentiation phase (scale bar =
100 μm). Red arrowheads directed at flat myoblasts in SOD1 cultures. (C) Immunocytochemistry (ICC) staining of
derived myoblasts for Pax7 and MyoD expression across all cell lines (scale bar = 50 μm). (D) ICC staining for
Desmin expression in WT and SOD1 cultures. (E) Flow cytometry (FC) result plots showing TBX6 expression
during the first week of differentiation (left panel) and PAX7 and MyoD expression by the third week of myoblast
differentiation (middle and right panels respectively). (F) Tabulated percentage values of FC results.
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Figure 6. Phenotypic Myotube Characterization. (A) Phase contrast images showing myotube derivation from
myoblasts from the three cell lines. Scale bar = 100 μm. (B) ICC images of myotube cultures stained for MyHC and
DAPI. Note the unfused background cells in the DAPI +/MyHC SOD1 cultures. Scale bar = 50 μm. (C) Bar graph
showing slightly decreased myotube cross sectional width compared in - SOD1 cultures relative to WT (Error bars
C.I. = 90%). (D) Average myotube thickness **P-value = 0.018. (E) Box and Whisker plots describing the lengths
of WT and SOD1 myotubes. P-value *** <0.001. One-way ANOVA, followed by Dunnett’s test. (F) Bar graph
showing fewer fusion events in the SOD1-mutant cultures compared to WT, evidenced by fusion index. (G) Bar
graphs indicating lower average myotube number per area in SOD1 cultures compared to WT. Error bars: SEM *
P<0.1; ** P<0.01; *** P <0.001 by Student T-test, 2 tails, unequal variance.
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Figure 7 Phenotypic Myotube Characterization. (A) ICC images of myotube cultures stained for MyHC and
+

-

Desmin. Notice that the unfused background cells in SOD1 cultures are Desmin /MyHC . Scale bar = 50μm.
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Figure 8. Phenotypic Myotube Characterization. (A) Myotubes stained for MyHC, nAChR and DAPI, depicting
diffuse to no AchR clusters in SOD1-mutant cultures. Yellow arrows point to nAChR clusters on SOD1 myotubes.
Nuclei staining (DAPI) showing decreased fusion in myotube cultures, as evidenced by MyHC-/DAPI+ unfused
myoblasts in the background Scale bar = 50μm.
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Figure 9. Functional Characterization of Myotubes. (A) Contraction traces of individual myotubes from iPSCderived SOD1 E100G, SOD1 L144P and WT control cultures at 0.3, 0.5, 1, 2 and 4Hz, on day 14 of myotube
differentiation. Electrical pulses were elicited at 1V for 15 seconds. (B) Bar graphs showing the percentage of
contraction synchrony at days 14. P ≤ 0.05 ANOVA on ranks followed by Holm-Sidak method. N.S. = not
significant.
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Figure 10 Functional Characterization of Myotubes. (A) Contraction traces of individual myotubes from iPSCderived SOD1 E100G, SOD1 L144P and WT control cultures at 0.3, 0.5, 1, 2 and 4Hz, on day 21 of myotube
differentiation. Electrical pulses were elicited at 1V for 15 seconds. (B) Bar graphs showing the percentage of
contraction synchrony at day 21. F. Videos of contracting myotubes P ≤ 0.05 ANOVA on ranks followed by HolmSidak method. N.S. = not significant.
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Figure 11. Functional Characterization of Myotubes. (A) Representative cantilever traces of WT and SOD1
myotubes. (B) Bar graph showing the contractile force per area of the respective WT and SOD1 muscle lines. (C)
Results depicting the time-to-peak force of WT and SOD1 muscle. *P < 0.1, **P- < 0.01, *** P< 0.001, One-way
ANOVA, followed by Dunnett's test.
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Figure 12. Mitochondria Functional Assessment. (A) TMRE assay measuring fluorescence intensity as a measure
of mitochondrial membrane potential at day 12 of differentiation. SOD1-mutant muscle exhibit decreased
mitochondrial membrane potential compared to WT Ctrl A. Error bars: SEM * P<0.1; ** P<0.01; *** P <0.001 by
Student T-test, 2 tails, unequal variance. (B,C) Mitochondrial metabolic rate assessment of SOD1 muscle for TCA
cycle intermediates and glucose-derived substrates. (D,E,F) Mitochondrial metabolic rate assessment of SOD1
muscle for amino acid-, fatty acid- and ketone-derived substrates respectively.
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CHAPTER THREE: PATHOLOGICAL CHANGES IN HUMAN ALS
SKELETAL MUSCLE AFFECT NEUROMUSCULAR JUNCTION
INTEGRITY AND FUNCTION
Introduction
Amyotrophic Lateral Sclerosis (ALS) is a debilitating adult-onset disease that typically
leads to death within 2-5 years of diagnosis [23]. This multi-faceted disease is characterized by
the progressive loss of upper and lower motoneurons, as well as skeletal muscle weakness and
wasting. While there is currently no cure for ALS, the FDA-approved treatments Riluzole and
Edaravone marginally extend patient life expectancy. Since the approval of Riluzole, dozens of
candidate ALS drugs have failed in clinical trials [62] [63]. One challenge in creating effective
ALS therapeutics has been the limited availability of models that effectively recapitulate human
disease conditions and reliably predict therapeutic outcomes in patients [64]. Additionally, the
paucity of information on ALS etiology, as well as symptom heterogeneity and disease
complexity further hamper the drug development process [65]. Therefore, there is an urgent need
to create models that can effectively recapitulate human disease pathology to help elucidate
disease etiology, develop more effective treatments and ultimately develop a cure for ALS.
To date, two types of ALS phenotypes have been described; familial ALS (fALS)
accounts for 10% of all ALS cases, while the remaining cases are labeled sporadic (sALS).
Familial ALS follows a Mendelian inheritance pattern which is usually autosomal dominant and
demonstrate an earlier onset of the disease among fALS patients, while the occurrence of sALS
is sporadic. Otherwise they are clinically indistinguishable [66], [67]. There are over 50 known
gene mutations including superoxide dismutase 1 (SOD1), fused in sarcoma (FUS),
chromosome 9 open reading frame 72 (C9orf72) and Tar DNA-binding protein (TARDBP),
which have been linked to both sALS and fALS cases [3, 68]. While the cause of ALS onset
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remains unresolved, researchers have identified NMJ dysfunction as one of the earliest events in
ALS progression [16, 27, 69, 70]. However, processes that induce NMJ dysfunction are not well
understood at this time, however, recent findings suggest the possible pathological involvement
of the skeletal muscle in ALS NMJ disruption [17, 71, 72]. Skeletal muscle-specific expression
of mutant SOD1 is reported to induce ALS-like symptoms such as decreased grip strength and
motoneuron degeneration, as well as NMJ dismantling in transgenic mice models [13, 15]. A
time-course study reported concurrent muscle atrophy and denervation prior to clinical symptom
onset and motoneuron death in ALS mice models [73]. Additionally, the axonal
guidance/repellent protein, Nogo-A, has been reported to be excessively secreted by ALS
skeletal muscle and has been shown to correlate with disease severity [12]. In addition, musclespecific delivery of myotrophic factors known to maintain motoneuron function improved NMJ
function and survivability in both patients and animal models, [17, 71, 74]. In a cell replacement
study, muscle satellite cells were reported to aid in the stability of the NMJ, and targeted
depletion of muscle satellite cell populations have been demonstrated to induce NMJ
degeneration [75]. ALS patient-derived hSKM satellite cells have been found to exhibit defective
regenerative function [72, 76, 77]. Although arguable, the above reports allude to the
pathological involvement of the skeletal muscle in ALS onset via NMJ disruption. This report
details the study of the pathological involvement of skeletal muscle in NMJ dysfunction,
utilizing previously characterized ALS patient induced pluripotent stem cell (iPSCs)-derived
skeletal muscle and motoneurons. Microphysiologic NMJ models were created by seeding each
cell type (i.e., healthy (WT) or ALS skeletal muscle matched with either WT or ALS
motoneurons) in separate chambers connected by microscopic tunnels that allowed the
progression of axons into hSKM chambers for NMJ formation, while permitting isolated
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interrogation and treatment of either cell type [72, 78]. Results demonstrated functional defects
in NMJ formation, stability, fidelity, and fatigability across all ALS NMJ models. However, the
outlined phenotype severity was comparatively enhanced in co-cultures with ALS hSKM (i.e.,
hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1). While functional NMJs were always recorded
in systems containing WT hSKM, paired with either WT or ALS hMNs, such events were only
observed about 30-60% of the time in systems containing ALS-hSKM, i.e., hSKMSOD1 –
hMNWT and hSKMSOD1 – hMNSOD1 co-cultures. Additionally, the NMJs in ALS-hSKMcontaining systems were about 50-70% unstable compared to the observed 20% in WT hSKMALS hMN co-cultures. These observations were also true for NMJ fidelity and fatigue.
Furthermore, ALS hSKM exhibited decreased acetylcholine receptor (AChR) clustering, which
did not improve even in co-culture with WT hMNs. The results demonstrate that intrinsic deficits
of the ALS hSKM contribute to NMJ dysfunction, thus supporting the view that the ALS hSKM
is an active contributor to ALS NMJ pathophysiology. Considering the phenotype severity of cocultures with ALS hSKM, the hSKM should be considered for therapeutic clinical targeting to
alleviate ALS symptoms and improve patient outcomes. The ability of these ALS NMJ models
to mimic clinically relevant NMJ dysfunction validates their use as platforms for personalized
etiological and pharmacological research and can be used in studying NMJ dysfunction in other
ALS-associated mutations.

Results
Co-culture Optimization
A series of experiments were performed to develop optimized plating protocols for
hSKM and hMN, their co-culture, and NMJ testing. The preliminary co-culture protocol
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stemmed from previous publications from our laboratory and other researchers [72] [40, 78]. The
first set of experiments investigated optimal seeding times and co-culture periods for hSKM and
hMN in the separate chambers of the NMJ platform. WT iPSC hSKM was plated into chambers
and allowed to proliferate for 3 days, after which the muscle cultures were switched to the
priming medium, DK-HI, for two days, followed by differentiation with N2 medium. IPSChMNs were seeded in the opposite chamber after 0, 2, or 5 days of muscle differentiation
initiation(Figure 15 A). Both medium types were refreshed every two days in the chambers until
the 14th day of hSKM differentiation such that cultures were in 14, 11 and 9 days of co-culture,
respectively. Co-cultures were functionally assayed for NMJ number and NMJ stability at each
co-culture time point. While 9 days of co-culture yielded the most NMJs, 14 days of co-culture
had relatively stable NMJs, meaning NMJs that had been in co-culture for 14 days would be
better able to withstand a rigorous testing regime (Figure 13A). While stability was relatively
better at day 14 of co-culture, it was still less than 50% (Figure 13 B). Contraction trace
assessment also indicated signs of hSKM fatigue post NMJ stimulation (Figure 13 C,D). As
hSKM-only cultures indicated no signs of weakness, it was apparent that the N2 differentiation
medium would not fully support NMJ function. Therefore, an alternative hSKM differentiation
medium and protocol were experimentally developed. The differentiation medium options tested
were myocult-DK-HI-N2, myocult-N2, myocult-DK-HI-NBA4+, and myocult-NBA4+. Based on
the results from the previous experiments, the two cell types were co-cultured for 14 days and
tested. Among all conditions investigated, chambers differentiated with myocult-DK-HI-NBA4+
yielded the highest average number of NMJs and demonstrated a relatively improved NMJ
stability (Figure 14 A, B). Additionally, muscle weakness was alleviated (Figure 14 C, D). Thus,
the established protocol for the skeletal muscle differentiation for subsequent experiments was as
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follows: myocult-DK-HI-NBA4+. The co-culture period was established to be 14 days (Figure 15
B).
NMJ Formation between iPSC- Derived Skeletal Muscle and Motoneurons
There is limited knowledge on the skeletal muscle’s role in ALS pathology. Although
there are reports pointing to the involvement of the hSKM in ALS onset and progression, there is
no explicit proof that demonstrates the induction of NMJ disruption via the hSKM [71]. With the
optimized protocol, the interaction between the hSKM and hMNs in NMJs was characterized to
gain insight on how ALS hSKM contributes to NMJ dysfunction. In addition to hSKMWT hMNWT co-culture, three variations of mutant co-cultures were included in the characterization
experiments. They are hSKMSOD1 – hMNWT, hSKMWT - hMNSOD1and hSKMSOD1 - hMNSOD1.
The co-cultures with one mutant tissue paired with healthy tissue (i.e., hSKMSOD1 – hMNWT,
hSKMWT - hMNSOD1) were included to investigate the effect of the specific tissue-type to ALS
NMJ integrity, while the mutant hSKM-mutant hMN co-culture was to study the additive effect
of the SOD1 mutation in both tissue types on NMJ function. Morphological representation is as
shown in Figure 15C. Immunocytochemical staining of iPSC hMNs axons with synaptophysin
and acetylcholine receptor staining on iPSC-derived hSKM with bungarotoxin-488 (BTX)
demonstrated close interaction of the two cell types, suggesting NMJ formation (Figure 16).
Functional NMJ testing at days 14 and 17 of co-culture validated the formation of NMJs.
Overall, NMJs were observed in all co-culture variations (Figure 17).
NMJ Number in SOD1-Mutant Cultures
One established phenotype of ALS is a progressive reduction in the number of motor
units [71]. The number of NMJs in hSKMSOD1 – hMNWT, hSKMWT - hMNSOD1 and hSKMSOD1 –
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hMNSOD1 were quantified at days 14 and 17 of co-culture. This was done by counting the number
of myotubes contracting in response to MN stimulus. On both co-culture days, hSKMSOD1 –
hMNSOD1 co-culture had the least number of NMJs, which were significantly lower than that of
hSKMWT – hMNWT co-cultures (Figure 17A, B). This was followed by hSKMSOD1 – hMNWT cocultures (Figure 17A, B). Likewise, NMJ numbers for hSKMWT - hMNSOD1 were significantly
lower than hSKMWT - hMNWT at day 14 of co-cultures. However, hSKMSOD1 L144P – hMNWT
exhibited a slightly lower number of NMJ, while hSKMSOD1 E100G – hMNWT maintained a
significantly lower NMJ number compared to controls on D17 of co-culture (Figure 17 B).
Another notable observation was the decreased tendency of NMJ formation in all co-cultures
with ALS hSKM (Figure 18). For instance, 32% of hSKMSOD1 L144P – hMNWT co-culture
chambers tested had functional NMJs recorded at day 14, which increased to about 59% by day
17. These numbers further decrease in SOD1L144P hSKM in co-culture with SOD1L144P hMNs to
30% vs. 32% for days 14 and 17 respectively (Figure 18). Similar trends were observed with the
SOD1E100G hSKM co-cultures, though recorded NMJ events of SOD1E100G hSKM co-cultures
were higher relative to those of SOD1L144Pco-cultures (Figure 18). Altogether, there is reduced
NMJ formation in ALS co-cultures, especially in the co-cultures with ALS hSKM.
NMJ Fidelity of SOD1-mutant cultures

NMJ fidelity, a measure of hMN-hSKM transmission reliability across the synapse which
is correlated for clinical ALS manifestation of spasticity and other movement deficits, was also
examined. This was to assess how the SOD1 mutation in either the hMN or hSKM affects the
functional integrity of the NMJ response to stimulus. NMJs in each co-culture condition were
assessed for their ability to contract consistently in response to increasing frequencies of hMN
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stimulation i.e., 0.33, 0.5, 1, and 2 Hz. Compared to hSKMWT - hMNWT co-cultures, all the ALS
NMJ models demonstrated reduced contraction fidelity, especially at higher stimulation
frequencies (i.e., 1 and 2 Hz) on both days 14 and 17 of testing (Figure 19, 20, 21, 22, 23, 24).
However, the co-cultures of hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1 NMJ had much
lower NMJ fidelities compared to hSKMWT - hMNSOD1 systems (Figures 20 B, C; 21 B, C;
Figures 23 B, C; 24 B, C). To identify whether contractibility inefficiencies of the ALS hSKM
contributes to NMJ fidelity defects , hSKM contraction fidelity was analyzed similarly but by
direct electrical stimulation of hSKM instead of MNs. As expected, direct hSKM traces from
hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1 co-cultures showed decreased contractile
fidelity on both days 14 and 17 of differentiation. Interestingly, WT hSKM co-cultured with
SOD1E100G hMNs generally exhibited a significant decrease in contraction fidelity (Figure 19C,
22C) while those cultured with SOD1L144PhMNs showed no signs of contraction fidelity,
suggesting some feedforward deteriorative signaling from hMNs to hSKMs, as well as the
phenotypic variations between different mutations (Figure 19C, 22C). The results demonstrate
functional NMJ disruption across all ALS systems, which is more severe in co-cultures with
ALS hSKM.
NMJ Stability in SOD1-Mutant Cultures
Another factor considered was the stability of the NMJs formed as decreased NMJ
stability has been reported in ALS clinical pathology [79]. Stability in the chambers was
determined by counting the number of NMJs remaining of the initial NMJ number after cocultures had been subjected to increasing frequencies of stimulation for 15 seconds each. This
parameter was measured to examine the ability of the various NMJ models to maintain a
functional synapse after strenuous activity. NMJ stability was calculated as the percentage of
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total number of NMJs post-testing divided by the total NMJ number pre-testing. While hSKMWT
– hMNWT NMJs remained relatively stable, there was reduced NMJ stability across all ALS NMJ
co-cultures (Fig 25). However, NMJ stability of hSKMWT - hMNSOD1 co-cultures was
comparatively less reduced than that of hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1. For
hSKMSOD1 – hMNWT co-cultures, the NMJ stability was well below 50% (Figure 25). The
average stability of hSKMSOD1 – hMNSOD1 co-cultures was approximately 21-31% at day 14,
which saw a slight improvement to about 30-44% by day 17 of co-culture (Figure 25 A, B).
While stability in SOD1L144Pcultures went from 39% to 42% between day 14 and 17, stability in
SOD1E100G cultures remained at approximately 42-43% on both days. HSKMWT - hMNSOD1 cocultures had comparatively high average stability of about 83-86% at day 14 and between 8286% at day 17.
Fatigue Index in SOD1-Mutant Cultures
Skeletal muscle weakness and increased fatigability are hallmarks of ALS or Lou
Gehrig’s disease [80]. It has been reported that increased fatigue in ALS skeletal muscle tension
is partially attributable to impaired excitation-contraction coupling or energy production, both of
which have been observed by aneural ALS hSKM studies [72, 81]. Since this is a clinically
measured parameter, the contribution of ALS hSKM to the NMJ fatigue index was assessed.
NMJ and hSKM fatigue indices were evaluated to determine how well contractions could be
sustained over time, specifically, at higher frequencies of stimulation (i.e., 1 and 2Hz). All ALS
co-cultures had significantly higher NMJ fatigue indices (on both days 14 and 17 of testing)
compared to hSKMWT – hMNWT (Figure 26,) except for hSKMWT - hMNSOD1 L144P at 1 Hz on day
14 in differentiation (Figure16 A). Similarly, there was generally high hSKM fatigue indices
across all ALS NMJ systems on both days 14 and 17, with the exception of hSKMWT - hMNSOD1
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systems. (Figure 27). Of note, the fatigue index in hSKMSOD1 – hMNSOD1 co-cultures was
comparatively higher than that of hSKMSOD1 – hMNWT and hSKMWT - hMNSOD1 cultures. These
results establish that deficits in the fatigue index are correlated with increased severity of NMJ
dysfunction in the presence of mutant skeletal muscle.

Discussion
Neuromuscular junction (NMJ) dysfunction has been identified as an early event in
Amyotrophic Lateral Sclerosis (ALS) pathogenesis. However, whether it is the mutations in
hMN or hSKM that induces NMJ dismantling is still being debated. Many are of the view that
NMJ dysfunction is a result of motoneuron pathology, which results in axonal retraction, which
in turn causes skeletal muscle weakness and wasting due to denervation [82]. However, recent
findings report pathological involvement of the hSKM in ALS onset and progression, refer to as
the dying-back phenomenon [23]. This study investigated the involvement of ALS hSKM in
pathogenesis of NMJ dysfunction in a human NMJ system using functionally relevant clinical
parameters. Myocentric (hSKMSOD1 – hMNWT and hSKMSOD1 - hMNSOD1), neurocentric
(hSKMWT - hMNSOD1) and healthy (hSKMWT - hMNWT) NMJ systems were developed by
incorporating healthy (WT) and patient iPSC-derived hSKM and hMNs into compartmentalized
constructs with axons innervating the hSKM through microtunnels. This bio-MEMs platform
was utilized as it allows NMJ formation while maintaining physical separation of hMN and
hSKM, thus permitting isolated chemical and electrical examination of either cell type [60, 78].
Results indicate the formation of functional NMJs in healthy and all ALS NMJ systems.
However, all ALS systems had significantly lower NMJ numbers, decreased NMJ stability,
reduced contraction fidelity, and increased fatigue index, which all have clinical correlates to
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ALS pathology. Of note, the outlined deficits were more pronounced in co-cultures with ALS
hSKM compared to those with ALS motoneurons. These results demonstrate that pathological
deficits in the ALS hSKM detrimentally affect NMJ integrity and function and emphasize the
need to more prominently consider hSKM as a therapeutic target in ALS drug development.
Furthermore, the patient iPSC-derived ALS NMJ models recapitulated pathological alterations
observed clinically and in transgenic models, making them suitable platforms for patient‐specific
etiological and pharmacological testing.
NMJ synapse formation begins with the contact of presynaptic motoneuron axon
terminals with post-synaptic pre-patterned AChR clusters. Once contact is made, pruning is
initiated, where un-innervated AChR clusters are removed, while innervated clusters expand and
are reinforced. The Agrin - Low-density lipoprotein receptor-related protein 4 (Lrp4) - MuscleSpecific Kinase (MuSK) signaling pathway facilitates this process and aids in the maintenance of
the NMJ throughout adulthood [83, 84]. Functional NMJ formation in all co-culture models was
confirmed by observing hSKM contraction in response to hMN-specific electrical stimulation.
This was possible because the two cell bodies of the hSKM and hMN were electrically and
chemically isolated by a PDMS barrier with tunnels that were only large enough to allow axonal
progression into hSKM chamber (Figure 15 A, C). While NMJs were observed in all ALS NMJ
chamber models, hSKMSOD1 – hMNWT and hSKMSOD1 - hMNSOD1 (Figure 17) had lower numbers
of NMJs relative to hSKMWT - hMNSOD1. However, the NMJ numbers recorded in hSKMWT –
hMN SOD1 L144P, hSKMSOD1 L144P – hMNWT and hSKMSOD1 L144P – hMN SOD1 L144P co-cultures
increased between days 14 and 17 of testing. Conversely, there was either no change or a
decrease in NMJ numbers for SOD1E100G co-cultures between days 14 and 17 of testing. This
consistent difference in behavior between the two SOD1 mutant NMJ systems was previously
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outlined in an ALS muscle study published by our group [72]. It was remarkable that the
heterogeneity between SOD1L144Pand SOD1E100G remained consistent even with hMN
stimulations. Investigation into alterations conferred by either SOD1 mutation revealed that
SOD1E100G has an increased propensity of forming protease-resistant aggregates and is linked to
relatively more aggressive forms of ALS with shorter disease duration, while SOD1L144F had a
moderate aggregate-forming likelihood, associated with later disease onset [85-87]. It is
important to note that while functional NMJs were observed in all co-culture models, not all
hSKMSOD1 – hMNWT and hSKMSOD1 - hMNSOD1 co-cultures yielded functional NMJs
consistently. NMJ events were recorded in 35-60% of the hSKMSOD1 chambers tested, while
NMJ events were observed in all hSKMWT - hMNSOD1 and hSKMWT - hMNWT co-cultures
(Figure 18). This reduced propensity of NMJ formation is likely a result of reduced AChR
clustering on the SOD1 myotubes (Figures 16 iv-vii). Immunocytochemical staining with
synaptophysin and bungarotoxin exhibited highly branched terminals in specifically the
hSKMSOD1 – hMNWT co-culture model. The WT hMNs axons appeared to wrap around the
length of ALS myotubes before extending to other myotubes, but hSKMSOD1 - hMNSOD1 models
had fewer hMN axons terminals interacting with myotubes. Interestingly, ALS hSKM in coculture with either WT or SOD1 hMNs demonstrated no improvement in myotube morphology
or AChR clustering. This is contrary to the expected result, especially in the presence of neuronal
agrin, which is expected to improve AChR clustering [83, 84]. A similar observation was made
by Picchiarelli et al, during their study of the effect of mutant Fused in Sarcoma (FUS) in
endplate maturation in the skeletal muscle, where FUS function was linked to AChR expression.
In their study, endplate maturation impairment was reversed upon correcting mutations in FUS
[22]. Unlike FUS, there is no known direct link between the presence of SOD1 gene and AChR
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expression and clustering to the best of our knowledge. Thus, it will be an interesting subject for
future study.
Another parameter assessed was NMJ stability. The reliable transmission of action
potentials (AP) from the motoneurons to the skeletal muscle is critical for voluntary movement
to the body [88]. NMJ synaptic transmission is a highly organized process that requires
cooperation between the presynaptic neuron and the post-synaptic skeletal muscle. In the
motoneuron, synaptic vesicles are released in response to an influx of Ca2+ following the
depolarization of the axonal terminal membrane. The persistent release of the Ach-containing
vesicles upon each depolarization after an elongated period of stimulation is contingent on
efficient transport of these vesicles from the motoneuron soma [88]. On the post-synaptic end,
the continuous propagation of the chemical synapse is dependent on the successful docking of
the released Ach on its receptors located on the skeletal muscle membrane. This action in turn
depolarizes the skeletal muscle membrane via the influx of Na+, which then leads to the
initiation of the excitation-contraction (EC) coupling, thus allowing the skeletal muscle to elicit
contractions in response to electrical stimulus originating from the motoneuron. Any defect in
this concerted mechanism decreases the reliability of synaptic transmission. While a decrease in
NMJ stability was observed in all the ALS NMJ systems, hSKMSOD1 – hMNWT and hSKMSOD1 hMNSOD1 NMJ co-cultures had more drastic reductions in stability compared to hSKMWT hMNSOD1, which dropped by only about 20% compared to hSKMWT - hMNWT (Figure 25).
Decreased NMJ stability in hSKMWT - hMNSOD1 co-cultures is likely to be a result of disruption
in pre-synaptic AP transmission and decreased mitochondrial function. Altered mitochondrial
function as well as noticeable amounts of damaged mitochondria have been reported in ALS
motoneurons [89-91]. Energy is vital for the function of cellular processes. Thus,
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reduced/dysfunctional energy production may impair neuronal function. Additionally,
aggregation of mutant proteins complexed with accumulated neurofilament (NF) and
mitochondria has also been reported in ALS patients and transgenic animal models (reviewed by
[91]. These aggregates are believed to alter the physiology of motoneurons by disrupting anteroand retrograde transport within the cell. In addition to protein inclusions, dynactin-1, a
component of axonal transport complex, is downregulated in sporadic ALS patients [92]. These
changes in mitochondrial function coupled with impaired axonal transport can retard cellular
homeostasis, which negatively impacts the pre-synaptic propagation of action potentials. In
addition, NMJ instability in hSKMSOD1 – hMNWT is attributable to impaired innervation, postsynaptic AP transmission, contractibility upon excitation-contraction coupling (E.C.C), and the
force of contraction [72]. Post-synaptic endplate maturation was found to be impaired in ALS
muscle co-cultures, where AChR clusters on ALS myotubes were small and/or diffuse. Altered
post-synaptic skeletal muscle membrane has also been reported in ALS [22, 72]. Decreased postsynaptic AChR clustering decreases the propensity of robust hSKM-hMN synapse formation,
which obstructs AP transmission and NMJ function. Disturbances in energy metabolism in ALS
hSKM is another factor that may impact NMJ stability. Contraction in response to AP reaching
the hSKM is an energy dependent process. Mitochondrial respiratory chain dysfunction is an
established phenomenon in ALS hSKM (reviewed by Manzano et al, [93] . There is evidence to
suggest that reduced ATP generation as a result of defective mitochondrial activity underlies
some aspects of NMJ dysfunction and instability in ALS pathology [72, 94].
Contraction traces across all ALS models demonstrated significantly decreased NMJ
fidelity compared to hSKMWT - hMNWT co-cultures (Figures 19, 20, 21, 22, 23, 24). Direct
hSKM stimulation of diseased hSKM in co-cultures (i.e., hSKMSOD1 – hMNWT and hSKMSOD1 47

hMNSOD1) also exhibited fidelity deficits (Figures 20C, 21C, 23C, 24C). Notably, hSKMSOD1 hMNSOD1 co-cultures demonstrated a much-pronounced reduction in NMJ fidelity, due to
pathological contribution of both tissue types. On the contrary, hSKMWT - hMNSOD1 had a milder
NMJ fidelity phenotype relative to hSKMSOD1 – hMNWT and hSKMSOD1 - hMNSOD1. Reduction in
contraction fidelity indicates a reduced tendency for ALS NMJs to sustain a steady function over
time. In clinical conditions, this manifests as spasticity and limited ability to perform basic
movement tasks [78]. Concomitant with the fidelity results, increased NMJ fatigue was observed
across all ALS co-cultures. Fatigue indices of hSKM in hSKMSOD1 – hMNWT and hSKMSOD1 hMNSOD1 co-cultures were also significantly increased (Figure 27). Notably, cultures with
mutations in both tissues (i.e., hSKMSOD1 - hMNSOD1) had comparatively more severe NMJ
fatigue pathology than either hSKMWT - hMNSOD1 or hSKMSOD1 – hMNWT (Figure 26). A notable
observation was significant contraction asynchrony on the NMJ and hSKM level in hSKMSOD1 –
hMNWT co-cultures. Although not completely understood, it is worth noting that significant
reductions in fidelity were seen in WT hSKM in co-culture with SOD1E100G hMNs (Figures 19C,
22C). This observation was true on both days 14 and 17 of testing. One study reported observed
atrophy in human skeletal muscle in co-culture sporadic ALS hMN [95]. Although it may be
linked to factors such as increased protein aggregation propensity prion-like secretion, and
observed phenotypic severity associated with the E100G mutation, further experimentation will
be necessary to address this question. it is unclear how diseased motoneuron can induce
dysfunction in healthy hSKM.
Skeletal muscle weakness and wasting are generally viewed as a result of hMN
denervation [54]. However, the points outlined above demonstrate how the intrinsic
morphological and functional deficits of the ALS skeletal muscle affect the human NMJ integrity
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and function. Additionally, this work shows how symptom severity is heightened in the presence
of the ALS hSKM where, the ALS hSKM cannot be viewed as a victim of neuronal dysfunction
but may be an active disease propagator. Thus, the ALS skeletal muscle should be considered in
developing therapeutics, as improving ALS skeletal conditions may help alleviate symptom
severity. It must be noted that, ALS is a heterogeneous disease with numerous associated genetic
mutations. While this work focuses on mutations in the SOD1 gene, the microfluidic platform
described in this work can be utilized in exploring other ALS-associated mutations as well as
sporadic ALS. The platform can also be extended to include other cell types linked to ALS like
astrocytes, Schwann cells and microglia in effort of closely recapitulating disease condition in
vitro.

Materials and Methods
Chamber Fabrication, Assembly and Surface modification
Chambers were cast from polydimethylsiloxane (PDMS) and cut according to previously
published dimensions [60]. These chambers were soaked in 70% isopropyl alcohol to facilitate
leeching. After 24 hours, the chambers were rinsed with and stored in sterile water till use. Upon
use, chambers were sterilized and bonded to plasma-cleaned glass coverslips by pressing firmly.
The muscle and motoneuron sides of the chamber was coated with collagen I (100ul Col I,
4.9mls 1x PBS, 6ul acetic acid) and laminin (3ug/ml in 1x PBS) plating respectively. Collagen I
and laminin substrates were incubated on the surfaces overnight at 4◦C. Both chambers in each
system was carefully rinsed with 1x PBS in preparation for culture plating.
Cell Co-culture and Maintenance
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WT and SOD1 myoblasts were plated at 400 cells/mm2 in Myocult medium (DMEM 1000mg/L
plus Myocult-SF supplement) until confluence, after which cultures were switched to DK-HI
medium (as prepared in a previous publication [96]. Muscle cultures were subjected to terminal
differentiation after two days in in DK-HI medium. Motoneurons were plated at 1500 cell/mm2
in human motoneuron (hMN) medium in the laminin-coated chamber the same day of muscle
differentiation induction [97]. Both cell types were maintained in their respective media until
days 14 and 17 when the cocultures were assayed/ tested.
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Table 1 List of Cell Culture Reagents

Reagents
MyoCult™-SF Expansion 10x Supplement (Human)
DMEM with 1000 mg/L D-Glucose
Collagen I, rat tail
Acetic acid
PBS (10X), pH 7.4
DMEM-F12
Dexamethosone powder
KnockOut™ Serum Replacement
2-Mercaptoethanol
Recombinant Human HGF
LONG® R3 IGF-I human
MEM Non-essential Amino Acid Solution (100×)
Insulin-Transferrin-Selenium (ITS -G) (100X)
L-Glutamine (200 mM)
NbActiv4
N-2 Supplement (100X)
Laminin
Antibiotic-Antimycotic

Vendors
Stemcell Technologies
Stemcell Technologies
Thermo Fisher Scientific
Sigma Aldrich
Thermo Fisher Scientific
Thermo Fisher Scientific
Sigma Aldrich
Thermo Fisher Scientific
Thermo Fisher Scientific
Peprotech
Sigma Aldrich
Sigma Aldrich
Thermo Fisher Scientific
Thermo Fisher Scientific
Brain Bits
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific

Catalog #
5982
36253
A1048301
A9967
70011044
21041-025
D4902
10828-028
21985023
100-39
I1271
11-140-050
41400045
25030081
NB4-500
17502048
23017015
15240-062

NMJ Testing and Quantification
iPSC-hMN & hSKM co-cultures were maintained in their respective differentiation
media for 14 days after which cultures were tested for NMJ formation. NMJ formation was
determined if skeletal muscle contraction events were observed upon electrically stimulating the
motoneurons. Prior to electrical testing, TEER measurements were taken with EVOM2™
Epithelial Voltohmmeter (World Precision Instrument) to ensure resistance is high enough to
prevent electrical leakage between chambers. TEER measurements greater than 5,000 ohms
were tested, while those with lower than 5000 ohms were eliminated. After the electrical leakage
test, cultures were tested. After scanning and counting the number of NMJ junctions formed, one
NMJ is selected, with which a series of tests were ran to determine the stability of the formed
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NMJs. On the selected NMJ, electrical stimulations are elicited in the motoneuron chamber at
increasing frequencies of 0.33, 0.5,1, and 2Hz, for 15 seconds per frequency, while the skeletal
muscle chamber is monitored for contractions in response to motoneuron stimulus. Each
chamber is pulsed post-test to count the number of remaining NMJs, after which the skeletal
muscle chamber is directly stimulated electrically at the frequencies listed above to validate
previously recorded NMJ traces. The average number of NMJs is quantified by finding the mean
number of pre-test NMJ number. NMJ stability in each chamber is determined by finding the
percentage of post-test NMJ number divided by the pre-test number of NMJs. Fidelity of both
NMJ and skeletal muscle contraction was accounted by assessing the percentage of observed
number of contractions divided by expected number of contractions at each stimulation
frequency. Also, fatigue index at the NMJ and skeletal muscle levels were calculated by
subtracting area under curve ((AUC) divided by peak force multiplied by time from one i.e.,
𝐴𝑈𝐶

[1 − (𝑃𝑒𝑎𝑘 𝐹𝑜𝑟𝑐𝑒 ∗ 𝑇𝑖𝑚𝑒)] at 1 and 2 Hz.
Immunocytochemistry
NMJ cultures were fixed following testing and stained for synaptic markers. To do this,
medium on both sides of the chambers were removed and replaced 4% paraformaldehyde
solution for 15 minutes. Once rinsed thrice with 1x PBS, the cultures were permeabilized with
0.1% Triton-X solution for 15 minutes, followed by a blocking step with donkey serum blocking
buffer (2.5% donkey serum, 1% bovine serum albumin) for an hour. Primary antibodies (MyHC,
1:30) were applied and incubated at 4 ˚C overnight, which was rinsed thrice with 1x PBS the
next morning. Secondary antibodies were applied at 1:250 and incubated at room temperature for
two hours. Bungarotoxin‐488 (BTX) (ThermoFisher) was added in the secondary antibody step
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at a 1:100 ratio. DAPI (1:1000) was added during the second of three rinses of following
secondary antibody incubation. Each chamber was then inverted and immersed in 1x PBS for
imaging. Cultures were imaged using the Zeiss Axioscope Spinning disk confocal microscope
with the help of Volocity software (Perkin Elmer).
Table 2 Antibodies and buffer used in Immunohistochemistry

Antibodies and Buffer
MYH1 Antibody
Synaptophysin Polyclonal Antibody
α-Bungarotoxin, Alexa Fluor™ 488 conjugate
Alexa Fluor 568,Donkey anti-Rabbit
Donkey Serum

Vendors
DSHB
Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific
Sigma Aldrich

Catalog #
A4. 1025
PA1-1043
B13422
A10042
s30-100ml

Statistical Analysis
Error bars on graphs represent the standard error of the mean (SEM). One‐ or two‐way
ANOVA tests were performed were performed where appropriate, followed by post-hoc
Dunnett's test. Statistical assessment was performed using GraphPad Prism 5. Graphs were
created with GraphPad Prism 5 and MS Excel.
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Figure 13: iPSC NMJ co-culture period optimization experiment in N2 medium. (A) Pre- and post-test number of NMJs with different co-culture periods. (B)
Percent stability of NMJs different co-culture periods. (C)Traces from NMJ experiment. (D) Traces from un-innervated muscle stimulation. Error bars = SEM
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Figure 14: iPSC NMJ co-culture medium experiment. (A) Pre- and post-test number of NMJs of varying medium sequences. (B) Percent stability of NMJs in
varying medium combinations. Error bars = SEM C)Traces from N2 condition. (D) Traces from NBA4+ condition. Error bars = SEM
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Figure 15: (A) Cartoon demonstration of the microfluidic NMJ co-culture system. (B) Illustration of iPSC NMJ co-culture plating and testing timeline. (C) Phase
images of the various coculture conditions and cell lines used in the study at day 13 of co-culture and differentiation. Scale bar = 100µm.
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Figure 16: Immunocytochemical staining of nicotinic acetylcholine receptors (nAChR)-green on skeletal muscle and synaptophysin red, a neuron axonal marker,
to demonstrate the formation of NMJs in the chambers. Scale bar = 50µm.
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Figure 17: Average NMJ Number assessment of hSKMWT hMNSOD1, hSKMSOD1 hMNWT, and hSKMSOD1 hMNSOD1 co-cultures across all cell lines at days 14 (A)
and 17 (B) of NMJ testing. One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01, ***p< 0.001
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Figure 18: Quantification of the NMJs per 100 chambers tested for (A) hSKMWT hMNSOD1, (B) hSKMSOD1 hMNWT and (C) hSKMSOD1 hMNSOD1 co-cultures
across all cell lines at days 14 and 17 of NM testing. Two-way ANOVA. *p< 0.05, **p< 0.01, ***p< 0.001
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Figure 19: Analysis of NMJ fidelity in D14 NMJ systems with SOD1 hMNs. (A.) Myotube contraction traces under MN stimulation (for NMJ function, top
traces) or SKM stimulations (for SKM function, bottom traces) in the co-cultures of hSKMWT hMNWT and hSKMWT hMNSOD1 across all cell lines at day 14. (B.)
Quantification of the average NMJ contraction fidelity across all co-cultures and cell lines at day 14. (C.) Quantification of the average hSKM contraction
fidelity across all co-cultures and cell lines at day 14 under direct electric stimulation on muscle. One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01,
***p< 0.001
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Figure 20: Analysis of NMJ fidelity in D14 NMJ systems harbouring SOD1 hSKM. (A.) Myotube contraction traces under MN stimulation (for NMJ function,
top traces) or SKM stimulations (for SKM function, bottom traces) in the co-cultures of hSKMWT hMNWT and hSKMSOD1 hMNWT across all cell lines at day 14.
(B.) Quantification of the average NMJ contraction fidelity across all co-cultures and cell lines at day 14. (C.) Quantification of the average hSKM contraction
fidelity across all co-cultures and cell lines at day 14 under direct electric stimulation on muscle. One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01,
***p< 0.001
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Figure 21: Analysis of NMJ fidelity in D14 NMJ systems with both SOD1 MNs and SOD1 SKM. (A.) Myotube contraction traces under MN stimulation (for
NMJ function, top traces) or SKM stimulations (for SKM function, bottom traces) in the co-cultures of hSKMWT hMNWT and hSKMSOD1 hMNSOD1 across all cell
lines at day 14. (B.) Quantification of the average NMJ contraction fidelity across all co-cultures and cell lines at day 14. (C.) Quantification of the average
hSKM contraction fidelity across all co-cultures and cell lines at day 14 under direct electric stimulation on muscle. One-way ANOVA. Error bars = SEM. *p<
0.05, **p< 0.01, ***p< 0.001
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Figure 22: Analysis of NMJ fidelity in D17 NMJ systems with SOD1 hMNs. (A.) Myotube contraction traces under MN stimulation (for NMJ function, top
traces) or SKM stimulations (for SKM function, bottom traces) in the co-cultures of hSKMWT hMNWT and hSKMWT hMNSOD1 across all cell lines at day 17. (B.)
Quantification of the average NMJ contraction fidelity across all co-cultures and cell lines at day 17. (C.) Quantification of the average hSKM contraction
fidelity across all co-cultures and cell lines at day 17 under direct electric stimulation on muscle. One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01,
***p< 0.001
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Figure 23: Analysis of NMJ fidelity in D17 NMJ systems with SOD1 SKM. (A.) Myotube contraction traces under MN stimulation (for NMJ function, top
traces) or SKM stimulations (for SKM function, bottom traces) in the co-cultures of hSKMWT hMNWT and hSKMSOD1 hMNWT across all cell lines at day 17. (B.)
Quantification of the average NMJ contraction fidelity across all co-cultures and cell lines at day 17. (C.) Quantification of the average hSKM contraction
fidelity across all co-cultures and cell lines at day 17 under direct electric stimulation on muscle. One-way ANOVA. Error bars = SEM.
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Figure 24: Analysis of NMJ fidelity in D17 NMJ systems with SOD1 hMNs and SOD1 hSKM. (A.) Myotube contraction traces under MN stimulation (for NMJ
function, top traces) or SKM stimulations (for SKM function, bottom traces) in the co-cultures of hSKMWT hMNWT and hSKMSOD1 hMNSOD1 across all cell lines
at day 17. (B.) Quantification of the average NMJ contraction fidelity across all co-cultures and cell lines at day 17. (C.) Quantification of the average hSKM
contraction fidelity across all co-cultures and cell lines at day 17 under direct electric stimulation on muscle. One-way ANOVA. Error bars = SEM. *p< 0.05,
**p< 0.01, ***p< 0.001
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Figure 25: Quantification of the average NMJ stability of in the co-cultures of hSKMWT hMNWT, hSKMWT hMNSOD1, hSKMSOD1 hMNWT and hSKMSOD1
hMNSOD1 across all cell lines at days 14 (A) and 17 (B) of NM testing. One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01, ***p< 0.001
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Figure 26: NMJ Fatigue index quantification for hSKMWT hMNWT, hSKMWT hMNSOD1, hSKMSOD1 hMNWT and hSKMSOD1 hMNSOD1 at Day 14 at 1Hz(A), 2Hz
(B) and Day 17 at 1Hz (C), 2Hz (D). One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01, ***p< 0.001
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Figure 27: hSKM Fatigue index quantification for hSKMWT hMNWT, hSKMWT hMNSOD1, hSKMSOD1 hMNWT and hSKMSOD1 hMNSOD1 at Day 14 at 1Hz(A), 2Hz
(B) and Day 17 at 1Hz (C), 2Hz (D). One-way ANOVA. Error bars = SEM. *p< 0.05, **p< 0.01, ***p< 0.001
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CHAPTER FOUR: THE EFFECT OF SKELETAL MUSCLE SPECIFIC
CREATINE TREATMENT ON ALS NMJ INTEGRITY AND FUNCTION
Introduction:
Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease is a multi-systemic, adult-onset
disease that leads to death within 2-5 years of diagnosis [23]. It is the commonest
neurogenerative diseases with about 5000 people diagnosed annually in the United States.
Although similar in many regards, ALS cases can be categorized into two groups: familial ALS
(fALS) and. sporadic ALS (sALS) . FALS cases form about 10% of all known ALS cases, and is
associated with earlier disease, while the remaining 90% of patients fall into the sALS category
[23]. While the etiology of the disease is not fully elucidated, dysfunction in many tissue types
including motoneuron, skeletal muscle, astrocytes, microglia, and Schwann cells have been
implicated in ALS pathology [23, 98].Currently, mutations in over 50 genes have been
associated with ALS. However, most patients with known genetic backgrounds have mutations
in chromosome 9 open reading frame 72 (C9orf72), Fused Sarcoma (FUS), Tar-DNA binding
protein 43, and Superoxide dismutase genes [99].
There is currently no cure for ALS despite decades of research. Existing FDA-approved
drugs, Riluzole and Edaravone only marginally improve the life expectancy of patients [100].
Thus, there is critical need for more effective therapeutic development. However, the lack of
disease models with translational capability that can recapitulate patient outcomes is one of the
main confounding challenges in ALS drug discovery efforts. Although transgenic animal models
have been instrumental in improving the field’s general understanding of the disease, they
generally fail to predict clinical efficacy and safety outcomes of therapeutics in patients.
Resultantly, numerous ALS therapeutics have failed in clinical trials[101] . Another challenge
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has been a lack of consensus on the pathogenesis of ALS. Some scientists purport ALS
progression to be a dying-forward mechanism while others claim a dying-back mechanism.
However, recent findings have scientists on both sides agreeing to one fact and it is that
neuromuscular junction disruption is one of the earliest disorders in ALS pathology [102]. As
much as this finding provides researchers a common site to begin tracing disease progression,
very little is known about the cause of NMJ dysfunction, thus, necessitating the need to
investigate factors involved in ALS NMJ dysfunction.
It has been reported that protein aggregates, down-regulation of transport proteins,
mitochondrial dysfunction which together result in impaired axonal transport contributes to NMJ
dysfunction by disrupting presynaptic action potential propagation [103] [104]. Other studies
have demonstrated intrinsic morphological and functional deficits in other tissues involved in the
tripartite synapse that could have direct impact on NMJ formation, maintenance and function
[22, 96, 102]. However, there is still doubt about the involvement of the ALS skeletal muscle or
Schwann cells in ALS NMJ dismantling [102]. To this end, we developed ALS patient derived
NMJ models on a BioMEMs platform to delineate the contribution of ALS hSKM and hMN to
NMJ dysfunction. While results indicated significantly reduced NMJ formation, NMJ stability,
contraction fidelity as well as increased fatigue index in co-cultures containing ALS hSKM or
hMN, observed functional defects in systems with hSKM were relatively more severe, thus
demonstrating the importance of the hSKM’s role in ALS NMJ integrity and function (Chapter
3. A consequential question we sought to address was whether specific therapeutic targeting of
the ALS hSKM confers any benefit to the human ALS NMJ.
Based on preliminary hSKM -only experimentation, Creatine was selected among four
drugs for subsequent NMJ experiments based on its demonstrated ability to improve ALS
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myoblast fusion and mitochondrial function. Previously characterized patient iPSC-derived NMJ
systems, hSKMWT - hMNWT, hSKMSOD1 E100G – hMNWT , hSKMSOD1 L144P – hMNWT, hSKMSOD1
E100G

– hMNSOD1 E100G and hSKMSOD1 L144P – hMNSOD1 L144P were utilized this project which

aimed to investigate the effect of therapeutic ALS hSKM improvement on ALS NMJ integrity
and function. Skeletal muscle-specific Creatine treatment demonstrated comparatively increased
NMJ number, contraction fidelity, and stability while decreasing NMJ fatigue indices across all
treated ALS NMJ systems. A morphological assessment of these Creatine-treated ALS NMJs
showed a significant increase in acetylcholine receptor cluster number per myotube as well as
size of the clusters. Findings from this study buttress the relevance of considering the ALS as a
active contributor to ALS NMJ dysfunction. The study also confirms the skeletal muscle as a
therapeutic target in ALS, using a number of clinically relevant functional parameters.
Additionally, it demonstrates this human based BioMEMs platform as suitable for investigating
multi-faceted diseases like ALS and for preclinical drug efficacy and toxicity screening.

Results
Effect of Therapeutics on ALS Myotubes
It is being increasingly acknowledged that ALS-associated mutations negatively impact
hSKM morphology, metabolism, and function. Among the reported deficits reduced fusibility,
lower force output and decreased mitochondrial function are commonly reported across many
different ALS mutation. Interestingly, all these defects can directly or indirect linked to linked to
oxidative stress [44, 45, 105, 106]. However, there is limited knowledge about how existing ALS
therapeutics affect diseased muscle morphology and function.[107, 108] . Thus, the therapeutic
effect of reactive oxygen species (ROS) scavengers, Edaravone (an FDA-approved ALS drug)
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and 4-Hydroxy Tempo (Tempol) on ALS hSKM as well as two supplements used in the
management of ALS , Deanna Protocol (DP), and Creatine (Cr) on the ALS hSKM weres
studied[109, 110]. The outcome of each drug was measured by quantifying myotubes formation
and mitochondrial function. These parameters were assessed based on previous experiments that
outlined decreased regeneration and mitochondrial dysfunction as deficits of the ALS hSKM
[96]. Aside DP, all other treatments were tested at varying concentrations to determine their
optimal concentration for our purposes. Concentrations of components in the DP cocktails had
been optimized in previous publications from our laboratory [110]. Skeletal muscle cultures
received treatment every two days until day 12 differentiation when mitochondrial function was
assayed. Aside Creatine-treated cultures ,all other drugs demonstrated a decreased myotube
number across all concentrations and cell lines (Figure 28). In the Creatine-treated condition,
there was a general dose-dependent increase in myotube number across all cell lines (Figure
28B). Mitochondrial function assessment indicated significantly improved inner mitochondrial
membrane potential (Δψm) in DP- and Creatine-treated conditions, while Edaravone- and
Tempol-treated cultures contrarily had decreased Δψm compared to untreated (Figure 29).
Considering that only Creatine had a positive outcome for both parameters evaluated, it was
chosen for subsequent NMJ experiments. NMJ experiments were performed with 5mM Creatine
because it was the least concentration to show significant change in myotube number and
mitochondrial function. Moreover, there was generally no significant difference between 5mM
and 40mM outcomes across parameters measured
Effect of ALS hSKM-specific Creatine Treatment on NMJ Number
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Preliminary hSKM-only experiments demonstrated significantly increased myotube
number in Creatine- treated cultures, which indicated improved fusibility of ALS myoblasts . To
assess whether this increase in myotube number affects NMJ formation, the number of NMJs
with or without Creatine supplementation was assessed on days 14 and 17 of co-culture. (Figure
30). It was found that hSKM-specific Creatine-treated cultures had notably higher NMJ numbers
in both SOD1L144P and SOD1E100G systems compared to untreated.(Figure 31) This was true for
both hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1 co-cultures on both days 14 and 17
differentiation. Interestingly, increased NMJ numbers were also noted in hSKMWT – hMNWT
systems treated with Creatine These results indicate that muscle-specific Creatine treatment
enhances NMJ formation in ALS cultures.
Effect of ALS hSKM-specific Creatine Treatment on NMJ Fidelity
The next clinically relevant parameter evaluated was NMJ fidelity. It is an estimation of
consistent motoneuron to skeletal muscle action potential transmission to evokes contraction at
increasing frequencies [109]. Select NMJs were tested at stimulation frequencies ranging from
0.33 to 2 Hz at 5V, for 15 seconds. Electrical pulses were elicited on the motoneuron side of the
chamber at 15 seconds per frequency while recording resultant contractions at the hSKM side of
the chamber. This protocol was repeated with the stimuli directly elicited on the hSKM side to
evaluate direct muscle function. Compared to untreated, hSKM-specific Creatine-treated systems
of both hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1 had increased NMJ fidelity on both
days 14 and 17 especially at higher frequencies (i.e., 1and 2Hz) (Figure 32 A, 33 A). Similarly,
direct hSKM assessment of Creatine-treated hSKM had higher contraction fidelity than untreated
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(Figure 32 B,33 B). Together, these results demonstrate that hSKM-specific creatine treatments
improve ALS NMJ contractility.
Effect of ALS hSKM-specific Creatine Treatment on NMJ Stability
The therapeutic effect of Creatine on NMJ stability was also assessed, as decline in NMJ
stability is a commonly reported ALS clinical symptom [111]. This parameter was measured to
evaluate preservation of NMJ function in ALS co-cultures following exposure to continuous
contraction stimulus at increasing frequency. NMJ stability was calculated as the number of
NMJs counted after continuous electrical stimulation divided by number of NMJs recorded
before sustained stimulation[96, 109]. Compared to untreated, NMJs in muscle-specific Creatine
treated ALS co-cultures were found to be more stable (Figure 34). These results demonstrated
that hSKM- specific Creatine treatment increases ALS NMJ stability.
Effect of ALS hSKM-specific Creatine Treatment on NMJ Fatigability
The last functional parameter assessed was NMJ fatigue. Increased fatigue and decreased
mechanical output are clinical phenotypes reported among ALS patients [112]. Increased fatigue
has been linked to poor patient prognosis and survivability [113, 114] .Thus, the therapeutic
effect of creatine on NMJ and hSKM fatigue was evaluated in our systems by measuring NMJ
and hSKM at higher frequencies of stimulation (i.e. 1Hz and 2Hz) as Fatigue index=1−[Area
under curve/(Peakforce ∗ Time)]. Results demonstrated relatively decreased fatigue indices in
most Creatine -treated systems on days 14 and 17 of co-culture, except in hSKMSOD1 E100G –
hMNSOD1 E100G at day 17 (Figure 35, 36). However, it is worth noting that the observed decrease
in fatigue index was not statistically significant in all instances. This observation was also true
for direct ALS hSKM fatigue index (Figure 35, 36).
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Effect of ALS hSKM-specific Creatine Treatment on AChR Cluster Number per Myotube and
Innervated AChR Cluster Size
Postsynaptic propagation of action potentials is dependent on the binding of acetylcholine
to its receptor on the skeletal muscle membrane. ALS skeletal muscle was previously reported to
have reduced AChR clustering, which could potentially affect synaptic transmission [96].
Having observed improved NMJ number, stability, fidelity and fatigability, post-synaptic end of
the NMJ was assessed to determine whether Creatine treatment had any therapeutic impact on
NMJ morphology. AChR cluster number and size were quantified in the treated condition and
compared untreated following immunocytochemical staining with myosin heavy chain,
synaptophysin, bungarotoxin conjugated to fluorophore 488 (Figure 37). ImageJ quantification
of the NMJs revealed enhanced post-synaptic AChR clustering with Creatine-treated condition
as evidenced by significant increase in AChR cluster size and increased cluster number per
myotube in the treated condition compared to untreated (Figure 38).

Discussion
The purpose of this study was to evaluate the therapeutic effect of muscle-specific Creatine
treatment on ALS NMJ integrity and function. Aside its general function in locomotion, posture,
breathing and gait, the skeletal muscle (hSKM) is a known major metabolic regulator and is
partly responsible for whole body homeostasis[115]. As such, any impairment to the organ has
detrimental effects on the entire organism. In many disease states, poor prognosis has been
linked to excessive skeletal muscle wasting. In ALS , rapid weight loss has been linked to shorter
survival times[116]. Impaired hSKM metabolism , morphology and function have been reported
to precede disease onset and to contribute to NMJ dysfunction. [14, 15, 117, 118]. However, it is
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often overlooked and rarely considered in ALS pre-clinical drug discovery efforts. This study
explored whether treatment targeted at improving the ALS skeletal muscle confers any benefit to
the NMJ.
The study was carried out on microfluidic ALS NMJ systems developed from healthy and patient
derived iPSCs, which have been previously characterized to have reduced NMJ formation
propensity, decreased contraction synchrony, diminished stability as well as increased
fatigability (chapter 3). Based on preliminary hSKM-only drug test that demonstrated enhanced
both myotube number and mitochondrial function in ALS and WT hSKM cultures, Creatine was
selected to be used for subsequent NMJ experiments (Figures 28, 29). Aside this, Creatine is
reported to increase energy availability, lean muscle mass, muscular strength, overall protein
expression, myogenic differentiation, intracellular Ca2+ handling, and survival in dystrophic
skeletal muscle cells in addition to inducing antioxidative defense in myotube cultures, [119122]. Thus, the effect of hSKM-specific Creatine treatment on the ALS NMJ was much
anticipated.
The first parameter evaluated was NMJ formation with Creatine supplementation. NMJ
regeneration and maintenance formation are known to be impaired in ALS[102]. However,
hSKM-specific Creatine treatment significantly increased NMJ numbers in both SOD1L144P and
SOD1E100G co-cultures for both hSKMSOD1 – hMNWT and hSKMSOD1 – hMNSOD1 compared to
untreated (Figure 31). This was true on both days 14 and 17 of co-culture. It is worth noting that
while an increase in NMJ number in hSKMSOD1 – hMNWT systems was expected since the
hSKM side of the chambers were treated (Figure 31 A,B), noting significantly increased NMJ
numbers in Creatine-treated hSKMSOD1 – hMNSOD1 co-cultures was surprising. This is because
the SOD1 hMNs remained received no direct treatment. However, immunocytochemical
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assessment of NMJs from treated and untreated conditions post-test provided clues to why such
observations were made. While there were no apparent changes to the hMN axons between
treated versus untreated in any of the ALS co-culture conditions, ALS hSKM in Creatine-treated
chambers had significantly larger AChR clusters compared to untreated (Figure 37, 38) .
Additionally , myotubes in the treated condition had comparatively higher AChR clusters per
myotube than the untreated (Figure 38 B). The formation of larger AChR clusters is likely a
result of a generally increased protein expression upon Creatine supplementation[122, 123].
Increased AChR clusters per myotube in turn enhanced NMJ formation possibilities in the
Creatine condition. Overall, Creatine supplementation boosted NMJ formation in ALS cocultures.
Although Creatine treatment increased NMJ formation, how well these NMJs functioned was a
matter of concern. Thus, NMJ fidelity, in treated versus untreated NMJ co-cultures was
evaluated. As previously described, ALS NMJs demonstrate significantly reduced NMJ fidelity
compared to hSKMWT – hMNWT to-cultures (chapter 3). However, NMJ fidelity increased with
hSKM -specific Creatine treatment, across all ALS systems on both days 14 and 17 co-culture
relative to untreated (Figure 32A, 33A). Similarly direct hSKM fidelity assessments showed a
positive outcome (Figure 32B, 33B). Based on morphological analysis, it is highly likely that the
observed improved contraction fidelity is a result of enhanced hSKM metabolism, calcium
handling and protein expression upon Creatine treatment, as opposed to improved pre-synaptic
transmission. It may be attributed to improved hSKM metabolism, [119, 120]. Beside the
significant increase in ALS hSKM Δψm observed upon Creatine dosing (Figure 29), other
studies have reported that Creatine mitigates ROS buildup by preventing mitochondrial
permeability transition (MPT) pore formation [124, 125]. Enhanced inner mitochondrial
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membrane potential implies increased electron transport chain activity, which in turn improves
ATP generation. Also, Δψm has a positive effect on mitochondrial calcium handling, which plays
a critical role in overall cell metabolism and function [126]. Additionally, increased
mitochondrial function coupled with the availability of Creatine as an energy buffer improved
ALS myotube formation, which is an energy-costly process [127]. A previously published work
from our laboratory demonstrated increased skeletal muscle contraction peak force and myosin
heavy chain expression with Creatine treatment, which may explain the observed improvement
in contraction fidelity and fatigue index in the Creatine-treated condition (Figures 32, 33) [122].
Another noteworthy observation was enhanced NMJ stability in Creatine-treated co-cultures
relative to the untreated ALS NMJs (Figure 34). This may also be attributed to improved postsynaptic endplate maturation as well as increased energy availability. ALS myotubes have been
reported to have reduced AChR clustering, which is critical in NMJ formation, maintenance and
synaptic transmission of action potentials [22, 96]. Increased AChR cluster number and size in
ALS NMJ co-cultures, in addition to improved mitochondrial function and energy availability
supports the relatively increased NMJ stability in Creatine-treated NMJ systems (Figures 37, 38).
A question still left unanswered is how Creatine is associated with AChR expression. While
there are no experiments that link Creatine supplementation and AChR upregulation to the best
of our knowledge, there are reports that show that AChR expression and peroxisome proliferatoractivated receptor-γ coactivator-1α (PGC-1α) are positively correlated [128]. Beside this, one rat
muscle study shows a marginal increase in PGC-1α mRNA expression upon Creatine
supplementation[122]. However, one human-based study has reported increased protein and
mRNA expression levels of p38 MAPK, an upstream regulator of PGC-1α are upregulated with
Creatine supplementation [129, 130]. Thus, this study may be the first to demonstrate an
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association between AChR expression/clustering and Creatine supplementation. Further
experimentation may be required to definitively understand this link.
All the same, it must be noted that while there was an overall improvement in contraction fidelity
and fatigue index for both NMJ and hSKM upon Creatine treatment, this increase was not always
statistically significant . Also, NMJ numbers and function in Creatine-treated chambers were not
totally rescued to levels comparable to healthy conditions. However, this Creatine study
demonstrated the critical role of hSKM in NMJ formation and maintenance. On the other hand,
this study suggests that solely focusing on improving one tissue type in a multifactorial disease
like ALS may not be an effective approach. Contrarily, targeting a mechanism described as
dysfunctional across all tissues involved in ALS pathology like the mitochondria, may be
promising. Another approach may be the utilization of combination therapies that target more
than one common pathway could prove effective. For instance, treatments that concomitantly
target ROS reduction and boosting energy levels may be more effective than one that solely at
either pathway.
Overall, this project demonstrates relevance of regarding the ALS hSKM as a possible
therapeutic target. It also indicates the need to wholistically approach ALS research (i.e.,
considering all factors involved) as opposed to the over emphasis on one tissue type. Lastly, this
work demonstrates the utilization of BioMEMs technology as a valuable means of recapitulating
complex human diseases like ALS and its outcomes for drug toxicological and efficacy
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Materials and Methods
Tissue derivation of IPSC-Derived Cell Source
All human hSKM myoblasts and motoneurons used in the study were generated from the
same iPSC cell lines (i.e., healthy/ wildtype A (ND41865), SOD1 L144P (ND39032) and SOD1
E100G (ND35662) purchased from the Coriell Institute, Camden, NJ. Each cell type was
generated using a serum-free small molecule directed protocols and were characterized for their
respective markers using immunocytochemistry and flow cytometry. Detailed discussion of the
differentiation and characterization of each cell types can be found in previous publications from
our laboratory [96, 109].
BioMEMs NMJ Chamber Fabrication and Assembly
NMJ chambers were constructed from glass bonded to PDMS casts as described in
previous publications from our laboratory [60, 109]. Briefly, PDMS mold cut-outs were allowed
to leach in 70% isopropyl alcohol overnight, after which they were rinsed in sterile water.
Chambers were made by firmly pressing down sterilized and dry PDMS cut-outs on plasmacleaned glass coverslips. The skeletal muscle and motoneuron sides of the chambers were coated
with collagen I (ThermoFisher A1048301) (100ul Col I, 4.9mls 1x PBS, 6ul acetic acid) and
Laminin (ThermoFisher 23017015) (3ug/ml in 1x phosphate buffered saline (PBS)) respectively
and allowed to incubate overnight at 4˚C prior to cell plating. Assembled chambers were brought
to room temperature the next day before rinsing either side of each chamber with 1x PBS in
preparation for cell plating.
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Cell Plating and Maintenance
Plating timelines established for each cell type is based on previous co-culture
optimization experiments (Chapter 3). The skeletal myoblasts were plated at 400cells/mm2,
following thawing and rinsing of chambers with 1x PBS. These myoblasts were allowed to
proliferate in in myocult medium (DMEM 1000mg/L , Stemcell technologies, 36253 plus
Myocult-SF supplement, Stemcell technologies 05982) for one day, after which they are
switched to priming medium, DK-HI (DMEM/F12 21041-025 ThermoFisher Scientific,
15%vol/vol Knockout Serum Replacement ThermoFisher Scientific 10828-028, 10 ng/ml
hepatocyte growth factor (HGF) Peprotech 315-23, 2 ng/ml insulin-like growth factor (IGF),
Sigma I1271, 0.1 mM β-mercaptoethanol, ThermoFisher Scientific 31350010, 1% MEM NonEssential amino acids Solution ThermoFisher Scientific 11140050 and 100 nM dexamethasone,
Sigma D4902), for 48 hours. Muscle cultures were then switched to differentiation medium
(NBActiv4, Brain Bits) on the same day hMNs are plated 1500cells/mm2 on their respective side
of the chamber in hMN medium [97]. Skeletal muscle-specific treatment with 5mM creatine
began at day 4 in differentiation and maintained in muscle cultures till days 14 and 17 of testing.
5mM Creatine (Sigma Aldrich, C0780). The iPSC hMNs were plated in the laminin-coated side
of the chamber, three days after hSKM plating and day 0 of hSKM differentiation. The hMNs
were maintained in hMN medium throughout the culturing period, with half medium changes
every other day.
ALS Skeletal Muscle Drug and Supplement Treatment
The effect of Deanna Protocol (DP) (L-arginine (310 × 10−6 m), α-ketoglutarate (310 ×
10−6 m), γ-aminobutyric acid (0.8 × 10−6 m), 5-hydroxytryptophan (0.8 × 10−6 m), and
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glutamate oxaloacetate transaminase (7100 mU L−1) [110], Creatine, Edaravone (an FDAapproved ALS drug) (Sigma, M70800) and 4-Hydroxy Tempo (Tempol) (Sigma, 176141) on
myoblast fusion and mitochondrial function were studied on ALS hSKM (SOD1 E100G, SOD1
L144P) only cultures in comparison to WT hSKM. Concentration ranges tested for each drug
was based on previous publications . iPSC hSKM myoblasts plated on 18 mm plasma-cleaned,
collagen-coated glass coverslips cultured as previously discussed until day 4 of differentiation
when drug treatments were started. At days 10 and 12 of differentiation, cultures in each
treatment condition were assessed for any improvement in myotube formation and mitochondrial
function respectively. Using ImageJ, the number of myotubes in each condition was quantified
from representative phase-contrast images taken across all cell lines. Aside DP cocktail which
had been optimized in previous publications from our laboratory, all other drug candidates were
tested within a range of concentrations based on literature. Creatine treatments concentrations
were 0, 0.5, 5 and 40mM, Edaravone at 0, 1, 10, and 100µM, while Tempol treatment
concentrations were 0, 0.01, 0.1, and 3mM. Dosing for each drug was done every two days till
day 12, when myotubes in both WT and ALS cultures were assayed for mitochondrial function.
NMJ Testing and Quantification
NMJ formation in all co-cultures were tested at days 14 and 17 of muscle differentiation.
To determine there is no electrical leakage between the hMN and hSKM sides of each chamber,
TEER measurements were taken with EVOM2™ Epithelial Voltohmmeter (World Precision
Instrument). Resistance measurements of 5,000 ohms was considered high enough to prevent
electrical leakage. NMJ formation was confirmed when skeletal muscle contraction was
observed in response to electrical pulsing of the motoneuron chamber. NMJs were selected and
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assessed for stability, fidelity, and fatigue after scanning and recording number of NMJs formed
in each chamber. Select NMJs were stimulated 0.33, 0.5, 1, 2 Hz at 15 seconds per frequency.
After stimulation at increasing frequencies, the number of NMJs were recounted, after which
skeletal muscle initially assessed for NMJ testing is directly tested for muscle function. Test
recordings were done on upright phase-contrast microscope (Zeiss Hal 100) hooked to a
Hamamatsu digital camera (model C8484-05G). NMJ number, stability and fatigue index were
measured as previously described by [96, 109].
Immunocytochemistry
NMJ cultures were fixed with 4% paraformaldehyde solution for 15 minutes following
testing and rinsed thrice with 1x PBS. The cultures were permeabilized with 0.1% Triton-X
solution for 15 minutes and blocked with donkey serum blocking buffer (2.5% donkey serum,
1% bovine serum albumin) for one hour. Primary antibodies (i.e., Myosin Heavy Chain (MyHC)
1:30 (DSHB, A4_1025), Synaptophysin (syn) 1:1000 Fisher Scientific, PA1-1043) were added to
the cultures and incubated overnight at 4 ˚C after which, they were rinsed thrice with 1x PBS.
Secondary antibodies were added at 1:250 following the rinses and incubated at room
temperature for two hours. Bungarotoxin‐488 (BTX) (ThermoFisher, B13422) was added in the
secondary antibody step at a 1:100 ratio. 4′,6-diamidino-2-phenylindole DAPI Fisher Scientific,
D1306 (1:1000) was added during the second rinse of three rinses post-secondary antibody
incubation to visualize cell nuclei. Each chamber was imaged inverted and immersed in 1x PBS.
Microscope used was using the Zeiss Axioscope Spinning disk confocal microscope with the
help of Volocity software (Perkin Elmer).
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Mitochondrial Function Assessment
Differentiated myotubes were incubated in 500nM tetramethylrhodamine (TMRE)
solution (Thermofisher Scientific, T669) at day 12 in differentiation for 30 minutes and rinsed
with 1X PBS prior to imaging. Fluorescence images of the myotube cultures were taken with a
Zeiss spinning disk confocal microscope (Axioskop 2 Mot Plus). The average fluorescence
intensity per myotube across all conditions was measured via imageJ, as suggested by Hammond
[131].
Acetylcholine Receptor number and Size Quantification.
Chambers used in the assessment were fixed for staining at day 17 of co-culture. NMJs
depicting co-localization of syn, MyHC, BTX and DAPI were imaged with Zeiss Axioscope
Spinning disk confocal microscope 40x magnification water immersion lens coupled with
Volocity software. AChR cluster size and number were quantified with ImageJ selection and
counter tools respectively.
Statistical Analysis
All error bars on graphs represent the standard error of the mean (SEM). Unpaired t-tests
were run to compare treated and untreated groups. Results from treated group was normalized to
the untreated group within each batch of experiment. Statistical assessment was performed using
GraphPad Prism 9 and MS Excel. Graphs were created with GraphPad Prism 9 and MS Excel.
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Figure 28: Average myotube number of treatments of iPSC hSKM with (A) Deanna Protocol (DP) (B)Creatine (C) Edaravone (D) 4-Hydroxy Tempo (Tempol).
Error bars: SEM *p < 0.1, **p < 0.01
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Figure 29: Scatter plots of the average inner mitochondrial membrane potential treatment measurement of iPSC ALS and WT hSKM with (A) Deanna Protocol
(DP) (B)Creatine (C) Edaravone (D) 4-Hydroxy Tempo (Tempol). Error bars: SEM *p < 0.1, **p < 0.01
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Figure 30: (A)Cartoon illustration of the NMJ chamber. (B) Experimental timeline for iPSC hSKM and hMN plating , and Creatine treatment. (C) Phase images
for hSKMWT hMNWT, hSKMSOD1 hMNWT and hSKMSOD1 hMNSOD1 with/ without Creatine. Scale bar =100µm
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Figure 31: Average NMJ number (A) hSKMWT hMNWT, (B) hSKMSOD1 hMNWT and (C) hSKMSOD1 hMNSOD1 with/ without Creatine treatment at 14 and 17 days
of differentiation. Error bars: SEM *p < 0.1, **p < 0.01
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Figure 32: Graphs of (A) NMJ and (B) hSKM fidelity of hSKM WT hMNWT, hSKMSOD1 hMNWT and hSKMSOD1
hMNSOD1 with/ without Creatine treatment at days 14 of differentiation. Error bars: SEM *p < 0.1, **p < 0.01
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Figure 33: Graphs of (A) NMJ and (B) hSKM fidelity of hSKM WT hMNWT, hSKMSOD1 hMNWT and hSKMSOD1
hMNSOD1 with/ without Creatine treatment at days 17 of differentiation. Error bars: SEM *p < 0.1, **p < 0.01
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Figure 34: Average NMJ stability (A), (B) hSKMWT hMNWT, (B) hSKMSOD1 hMNWT and (C), (D) hSKMSOD1 hMNSOD1 with/ without Creatine treatment at days
14 and 17 of differentiation, respectively. Error bars: SEM *p < 0.1, **p < 0.01
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Figure 35: Average NMJ and hSKM fatigue of (A) (B) hSKMSOD1 hMNWT and (C) hSKMSOD1 hMNSOD1 with/ without Creatine treatment at days 14 of
differentiation. (i) WT (ii) SOD1 E100G (iii) SOD1 L144P Error bars: SEM *p < 0.1, **p < 0.01
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Figure 36: Average NMJ and hSKM fatigue of (A) (B) hSKMSOD1 hMNWT and (C) hSKMSOD1 hMNSOD1 with/ without Creatine treatment at days 17 of
differentiation. (i) WT (ii) SOD1 E100G (iii) SOD1 L144P Error bars: SEM *p < 0.1, **p < 0.0
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Figure 37: ICC staining of AChR, Myotubes and hMN axons (A) (i) hSKM SOD1 E100G hMNWT and (ii) hSKMSOD1
E100G hMNSOD1 E100G (B) (i) hSKMSOD1 L144P hMNWT and (ii) hSKMSOD1 L144P hMNSOD1 L144P with/ without Creatine
treatment at days 17 of differentiation. Error bars: SEM.

94

Figure 38: Normalized nAChR(A) Cluster size (B) cluster number per myotube hSKM SOD1 hMNWT and hSKMSOD1 hMNSOD1 with/ without Creatine treatment at
days 17 of differentiation. Error bars: SEM *p < 0.1, **p < 0.01
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CHAPTER FIVE: GENERAL DISCUSSION
Although structurally small, the NMJ is a critical chemical synapse that enables
executing large tasks like lifting heavy objects and small ones like making a fist. Aside its
function in facilitating movement, the NMJ controls vital processes like breathing and
swallowing [132]. Thus, any disruption to the NMJ can have fatal consequences. The NMJ is
tripartite synapse consisting of hMNs, hSKM and Schwann cells. Synapse formation begins with
pre-patterning, which is when initial AChR cluster on the membrane of the surface of hSKM.
Growing axons are guided by these AChR clusters towards the hSKM. Once neuromuscular
contact is made, pruning begins. This is when innervated AChRs expand, unenervated ones are
eliminated, excessive axons are removed. and stability of the NMJ is established[83, 84]. From
this, it can be deduced that proper NMJ formation requires the appropriate functioning of each
cell type involved. For instance, neural agrin secretion is critical for establishing stable Without
neural agrin, hMN axons continuously grow, wander and fail to associate with AChR [133]. This
is because neural agrin regulates axonal growth by binding to MUSK, which in turn prevents
further growth [133]. On the other hand, this growth of axons toward the hSKM cannot happen
without pre-patterned AChRs. Independent of neuronal agrin, AChRs clusters form by
complexing with Rapsyn [134, 135]. Without Rapsyn, initial AChR clustering does not occur as
demonstrated in animal models [134]. Absence of MUSK, like Rapsyn results in diminished
AChR pre-patterning, as it initiates AChR clustering [134] This goes to show that efficient NMJ
formation is a team effort. Thus, it is rational to state that NMJ dysfunction is also
interdependent. However, the ALS hSKM being an active contributor of disease progression is
still doubted, as many are of the view that the hSKM is a secondary victim [24]. Thus, the
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overarching aims of the project was to first delineate deficits in the ALS hSKM independent of
neuronal innervation, and subsequently investigate how these defects affect NMJ integrity and
function. As reported above, the hSKM-only studies demonstrated that ALS hSKM is
morphologically, metabolically and functionally altered relative to WT (Figures 1-8). These
defects in the ALS hSKM affected NMJ formation, fidelity, stability and fatigue index regardless
of being co-cultured with WT or ALS hMN (Figures 13-23). Interestingly, immunocytochemical
assessment of NMJs in ALS hSKM-WT hMN co-cultures indicated no AChR clustering despite
the presence of WT neuronal axons (Figure 12) in comparison to clusters in aneural ALS
cultures (Figure 4). Although axons of the WT hMNs appeared to be wrapping around the ALS
hSKM, NMJ number, stability, and fidelity were notably lower, while NMJ fatigue was much
higher relative to WT hSKM-ALS hMN systems (Figures 13-23) This suggests that observed
functional deficits may be a result of post-synaptic dysregulation. Interestingly, co-cultures with
ALS hSKM-ALS hMN comparatively demonstrated the worst NMJ numbers, stability, and
fatigue index. Those results exhibited compounded effect of having ALS mutations in both tissue
types and its effect on NMJ function and integrity.
Having confirmed the active pathological role of the ALS hSKM in ALS NMJ
dysfunction, the option of pharmacologically targeting the hSKM for enhanced NMJ function
was explored. Preliminary screening of therapeutics for the experiment was performed with
ALS hSKM-only cultures. The drug of choice for subsequent experiments was chosen based on
its capability to improve myotube formation and mitochondrial function, as both processes were
found to be dysfunctional in ALS hSKM. Considering that the ALS lines used in the experiments
both bore mutations in the SOD1, a ROS scavenger, two antioxidants, Edaravone (an FDAapproved ALS treatment) and tempol, as well as two supplements, the Deanna Protocol and
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Creatine were tested. Creatine was selected as a result of improving both defective parameters
investigated, compared to untreated (Figures 24-25). ALS hSKM side of the NMJ co-cultures
were chronically dosed with 5mM Creatine every two days beginning at day 4 in differentiation
until they were tested on days 14 and 17 of co-culture (Figure 26). Compared to untreated NMJ
chambers, hSKM-specific Creatine-treated systems generally had significantly enhanced NMJ
formation and stability (Figures 27, 30). Additionally, there was notably improved NMJ fidelity
and fatigue index (Figures 28-29, 31-32). However, it should be noted that the observed changes
in NMJ fidelity and fatigue was not statistically significant in all conditions. One remarkable
observation was the statistically significant increased AChR clustering and cluster size observed
in Creatine treated systems versus untreated (Figures 33-34). These results allude that the
observed NMJ functional improvement upon Creatine treatment is highly probable consequence
of enhanced post-synaptic condition, as result of relatively increased mitochondrial function and
overall protein expression [53, 119, 122] Collectively, these results confirm the ALS hSKM as a
druggable target for ALS treatments. However, it also reveals that targeting only one tissue in a
disease with a heterogeneous nature like ALS may not be sufficient to attain the expected
therapeutic benefit.
Overall, this project demonstrated that the ALS hSKM has inherent defects that are
independent of motoneuron innervation. It also reports that these defects affect the function of
both the ALS hSKM and NMJ. Additionally, it establishes the hSKM as a pharmacological
target to be considered. Lastly, this project resulted in the development of phenotypic ALS NMJ
models completely derived from patient iPSCs. These models recapitulated morphological,
functional, and metabolic ALS outcomes previously described in patient and human-based
studies, thus indicating their translational capability. Therefore, it holds the promise of being a
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useful tool in ALS patient/mutation-specific research and drug screening While the relevance of
Schwann cells in synaptic transmission, axonal regeneration and NMJ maintenance is
acknowledged, it was excluded from this project, as the system development was restricted to the
tissues that are necessary and sufficient for NMJ formation[136]. However, it will be considered
in future studies
It must be noted that this BioMEMs approach offered a relatively cost-effective,
timesaving, and simplified avenue of studying a rather complicated subject. It afforded the
opportunity of generating different variations of the model necessary for addressing the research
question from human cells of the same source. Also, the compartmentalized co-culture approach
provides the researcher a unique ability of evaluating each cell type independently. Lastly, the
platform is scalable and therefore holds the prospect of being expanded to include other cell
types like Schwann cells as well as microglia or astrocytes for a more comprehensive
understanding of the NMJ system, and ALS disease progression respectively.
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